WO2012087833A1 - Hepatitis c inhibitors and uses thereof - Google Patents
Hepatitis c inhibitors and uses thereof Download PDFInfo
- Publication number
- WO2012087833A1 WO2012087833A1 PCT/US2011/065558 US2011065558W WO2012087833A1 WO 2012087833 A1 WO2012087833 A1 WO 2012087833A1 US 2011065558 W US2011065558 W US 2011065558W WO 2012087833 A1 WO2012087833 A1 WO 2012087833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclopropyl
- methanesulfonamide
- fluorophenyl
- alkyl
- imidazol
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 10
- 208000006454 hepatitis Diseases 0.000 title description 5
- 231100000283 hepatitis Toxicity 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 444
- 150000003839 salts Chemical class 0.000 claims abstract description 101
- 238000000034 method Methods 0.000 claims abstract description 59
- -1 cyano, hydroxy Chemical group 0.000 claims description 398
- 229910052736 halogen Inorganic materials 0.000 claims description 230
- 229910052739 hydrogen Inorganic materials 0.000 claims description 224
- 239000001257 hydrogen Substances 0.000 claims description 223
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 190
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 177
- 150000002367 halogens Chemical class 0.000 claims description 164
- 125000001424 substituent group Chemical group 0.000 claims description 144
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 139
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 109
- 125000000623 heterocyclic group Chemical group 0.000 claims description 86
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 71
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 65
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 59
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 53
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 49
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 47
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 45
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 44
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 40
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 37
- 229910052760 oxygen Inorganic materials 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 230000010076 replication Effects 0.000 claims description 18
- 229920002477 rna polymer Polymers 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 8
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000006456 halo alkyl cycloalkyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 3
- JVYGCACRCIDBPM-SCSAIBSYSA-N (3R)-3,4-dihydroxybutane-1-sulfonamide Chemical compound O[C@H](CCS(=O)(=O)N)CO JVYGCACRCIDBPM-SCSAIBSYSA-N 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- MEHWJEXEJPYTGS-ZCFIWIBFSA-N 2-[(2R)-oxolan-2-yl]ethanesulfonamide Chemical compound O1[C@H](CCC1)CCS(=O)(=O)N MEHWJEXEJPYTGS-ZCFIWIBFSA-N 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims description 2
- OVIZSQRQYWEGON-UHFFFAOYSA-N butane-1-sulfonamide Chemical compound CCCCS(N)(=O)=O OVIZSQRQYWEGON-UHFFFAOYSA-N 0.000 claims description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 2
- OFSFIXASTARXSY-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]methanesulfonamide Chemical compound COC1=CC=C(CNS(C)(=O)=O)C=C1 OFSFIXASTARXSY-UHFFFAOYSA-N 0.000 claims description 2
- RIKIJEFEHGUSIB-UHFFFAOYSA-N n-[2-(4-fluorophenyl)-3-(1h-imidazol-2-yl)-5-propan-2-yloxy-1-benzofuran-6-yl]-n-[(4-methoxyphenyl)methyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1CN(S(C)(=O)=O)C(C(=C1)OC(C)C)=CC2=C1C(C=1NC=CN=1)=C(C=1C=CC(F)=CC=1)O2 RIKIJEFEHGUSIB-UHFFFAOYSA-N 0.000 claims description 2
- YDFSWPQAEKSXDM-UHFFFAOYSA-N n-[5-cyclopropyl-2-(4-fluorophenyl)-3-(5-methyl-2,5-dihydro-1,2,4-oxadiazol-3-yl)-1-benzofuran-6-yl]-n-(2-methylsulfonylethyl)methanesulfonamide Chemical compound O1C(C)NC(C=2C3=CC(=C(N(CCS(C)(=O)=O)S(C)(=O)=O)C=C3OC=2C=2C=CC(F)=CC=2)C2CC2)=N1 YDFSWPQAEKSXDM-UHFFFAOYSA-N 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 claims 127
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 100
- 239000000543 intermediate Substances 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 229
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 189
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 163
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 110
- 239000012091 fetal bovine serum Substances 0.000 description 108
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 91
- 239000007787 solid Substances 0.000 description 79
- 235000002639 sodium chloride Nutrition 0.000 description 78
- 229910001868 water Inorganic materials 0.000 description 74
- 241000711549 Hepacivirus C Species 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 73
- 239000011541 reaction mixture Substances 0.000 description 71
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 70
- 125000001153 fluoro group Chemical group F* 0.000 description 65
- 229910052720 vanadium Inorganic materials 0.000 description 62
- 125000005843 halogen group Chemical group 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 46
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 45
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 44
- 239000012267 brine Substances 0.000 description 43
- 125000001309 chloro group Chemical group Cl* 0.000 description 43
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 43
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 42
- 125000004076 pyridyl group Chemical group 0.000 description 40
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 34
- 238000003556 assay Methods 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- 239000003921 oil Substances 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 238000011282 treatment Methods 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 23
- 239000005909 Kieselgur Substances 0.000 description 22
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 21
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 20
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 19
- 235000019441 ethanol Nutrition 0.000 description 19
- 150000002825 nitriles Chemical class 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- 235000011181 potassium carbonates Nutrition 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 125000000753 cycloalkyl group Chemical group 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 125000003226 pyrazolyl group Chemical group 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 208000005176 Hepatitis C Diseases 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 241001493065 dsRNA viruses Species 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 15
- 239000002002 slurry Substances 0.000 description 15
- 125000000335 thiazolyl group Chemical group 0.000 description 15
- 125000001544 thienyl group Chemical group 0.000 description 15
- 102000014150 Interferons Human genes 0.000 description 14
- 108010050904 Interferons Proteins 0.000 description 14
- 125000001041 indolyl group Chemical group 0.000 description 14
- 229940079322 interferon Drugs 0.000 description 14
- 125000000714 pyrimidinyl group Chemical group 0.000 description 14
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 13
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 13
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 12
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 229960000329 ribavirin Drugs 0.000 description 12
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 12
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 11
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 11
- 125000000842 isoxazolyl group Chemical group 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 125000002541 furyl group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 10
- 125000001624 naphthyl group Chemical group 0.000 description 10
- 125000001715 oxadiazolyl group Chemical group 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000003386 piperidinyl group Chemical group 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 8
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 8
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 8
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 8
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 8
- 150000002923 oximes Chemical class 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 7
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 7
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 7
- 125000000565 sulfonamide group Chemical group 0.000 description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 239000002274 desiccant Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 6
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 6
- 239000012280 lithium aluminium hydride Substances 0.000 description 6
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 6
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 description 6
- 238000000844 transformation Methods 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 description 5
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 150000002460 imidazoles Chemical class 0.000 description 5
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 5
- 150000004694 iodide salts Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 239000013605 shuttle vector Substances 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 4
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 4
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 4
- 229910052731 fluorine Chemical group 0.000 description 4
- 239000011737 fluorine Chemical group 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 description 4
- 125000002971 oxazolyl group Chemical group 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 3
- XUMWJQJGCFTJOE-UHFFFAOYSA-N 1-benzofuran-3-carbaldehyde Chemical class C1=CC=C2C(C=O)=COC2=C1 XUMWJQJGCFTJOE-UHFFFAOYSA-N 0.000 description 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- JFBMFWHEXBLFCR-UHFFFAOYSA-N 4-bromo-2-methylpyridine Chemical compound CC1=CC(Br)=CC=N1 JFBMFWHEXBLFCR-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 3
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical class BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical group C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 3
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 3
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 description 2
- XQJAHBHCLXUGEP-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C=C1 XQJAHBHCLXUGEP-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- QAZZSBPFRXXQPY-UHFFFAOYSA-N 3-methylsulfonylpropane-1-sulfonamide Chemical compound CS(=O)(=O)CCCS(N)(=O)=O QAZZSBPFRXXQPY-UHFFFAOYSA-N 0.000 description 2
- LNKBDFVSILQKSI-UHFFFAOYSA-N 4-Chloro-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Cl LNKBDFVSILQKSI-UHFFFAOYSA-N 0.000 description 2
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HSMOLMIBWHOASD-UHFFFAOYSA-N 5-hydroxypentane-1-sulfonamide Chemical compound NS(=O)(=O)CCCCCO HSMOLMIBWHOASD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 description 2
- 229940122604 HCV protease inhibitor Drugs 0.000 description 2
- 238000007341 Heck reaction Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- COERJHDMQUPDCV-UHFFFAOYSA-N [K].FB(F)F Chemical class [K].FB(F)F COERJHDMQUPDCV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- OUYYNZDOJHSQBW-UHFFFAOYSA-N cyanomethanimidamide Chemical compound NC(=N)C#N OUYYNZDOJHSQBW-UHFFFAOYSA-N 0.000 description 2
- 150000001925 cycloalkenes Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000022244 formylation Effects 0.000 description 2
- 238000006170 formylation reaction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 2
- VECXNXBOZXLDBL-UHFFFAOYSA-N indolizine-3-carbaldehyde Chemical compound C1=CC=CN2C(C=O)=CC=C21 VECXNXBOZXLDBL-UHFFFAOYSA-N 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- DDIZAANNODHTRB-UHFFFAOYSA-N methyl p-anisate Chemical compound COC(=O)C1=CC=C(OC)C=C1 DDIZAANNODHTRB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 150000003557 thiazoles Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DWNJWSPPORNJGV-UHFFFAOYSA-N (2-bromo-1,3-thiazol-5-yl)methanol Chemical compound OCC1=CN=C(Br)S1 DWNJWSPPORNJGV-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- YJEVAUSLDPCMNO-UHFFFAOYSA-N 1,6-dihydropentalene Chemical compound C1C=CC2=C1CC=C2 YJEVAUSLDPCMNO-UHFFFAOYSA-N 0.000 description 1
- HPEUGDZNJLIBFP-UHFFFAOYSA-N 1-bromo-2-methylsulfanylethane Chemical compound CSCCBr HPEUGDZNJLIBFP-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- RRJBARRRFGZDIX-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethanesulfonamide Chemical compound COC1=CC=C(CCS(N)(=O)=O)C=C1 RRJBARRRFGZDIX-UHFFFAOYSA-N 0.000 description 1
- DJUWIZUEHXRECB-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carbaldehyde Chemical compound BrC1=NC=C(C=O)S1 DJUWIZUEHXRECB-UHFFFAOYSA-N 0.000 description 1
- YYHRYECWWYONCH-UHFFFAOYSA-N 2-bromo-5-(bromomethyl)-1,3-thiazole Chemical compound BrCC1=CN=C(Br)S1 YYHRYECWWYONCH-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- FSJHVKYHGDAMOH-UHFFFAOYSA-N 2-methoxy-4-nitro-1-(2-phenylethynyl)benzene Chemical compound COC1=CC([N+]([O-])=O)=CC=C1C#CC1=CC=CC=C1 FSJHVKYHGDAMOH-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- CMRFJAMFEWYMKE-UHFFFAOYSA-N 2-oxaadamantane Chemical compound C1C(O2)CC3CC1CC2C3 CMRFJAMFEWYMKE-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- PJAIMBYNTXNOCN-UHFFFAOYSA-N 3,6-dibromo-1h-indole Chemical compound BrC1=CC=C2C(Br)=CNC2=C1 PJAIMBYNTXNOCN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- PEPWQLDCQDIASD-UHFFFAOYSA-N 3-iodo-6-nitro-2-phenyl-1-benzofuran Chemical compound O1C2=CC([N+](=O)[O-])=CC=C2C(I)=C1C1=CC=CC=C1 PEPWQLDCQDIASD-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- URBGNYUDQQDMRX-UHFFFAOYSA-N 3-methylsulfanylpropane-1-sulfonamide Chemical compound CSCCCS(N)(=O)=O URBGNYUDQQDMRX-UHFFFAOYSA-N 0.000 description 1
- URPLDQSNOHMLIP-UHFFFAOYSA-N 3-phenylmethoxy-1,2-oxazole-5-carbaldehyde Chemical compound O1C(C=O)=CC(OCC=2C=CC=CC=2)=N1 URPLDQSNOHMLIP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JRBAQAMOIBHJRP-UHFFFAOYSA-N 4,5,6,7-tetrahydro-3ah-indene Chemical group C1CCCC2=CC=CC21 JRBAQAMOIBHJRP-UHFFFAOYSA-N 0.000 description 1
- JNTVUHZXIJFHAU-UHFFFAOYSA-N 4-(Methylthio)-1-butanol Chemical compound CSCCCCO JNTVUHZXIJFHAU-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- GVXMPLUTWVZNRR-UHFFFAOYSA-N 4-methylpentane-1-sulfonamide Chemical compound CC(C)CCCS(N)(=O)=O GVXMPLUTWVZNRR-UHFFFAOYSA-N 0.000 description 1
- YUSVCVRGEYRMCK-UHFFFAOYSA-N 4-methylsulfonylbutan-1-ol Chemical compound CS(=O)(=O)CCCCO YUSVCVRGEYRMCK-UHFFFAOYSA-N 0.000 description 1
- WXVYSXRUNMAEHI-UHFFFAOYSA-N 4-methylsulfonylbutyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCCS(C)(=O)=O)C=C1 WXVYSXRUNMAEHI-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- XJVPYZYZBFJSJX-UHFFFAOYSA-N C(C)C1=C(OC2=C1C=C(C(=C2)N(S(=O)(=O)C)CC1=CC=C(C=C1)OC)C1CC1)C1=CC=C(C=C1)F Chemical compound C(C)C1=C(OC2=C1C=C(C(=C2)N(S(=O)(=O)C)CC1=CC=C(C=C1)OC)C1CC1)C1=CC=C(C=C1)F XJVPYZYZBFJSJX-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- 238000010485 C−C bond formation reaction Methods 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- OLEGOEGXXYVBGT-KQGICBIGSA-N [Li].C(C1=CC=CC=C1)OC1=NOC(=C1)/C=C/CO Chemical compound [Li].C(C1=CC=CC=C1)OC1=NOC(=C1)/C=C/CO OLEGOEGXXYVBGT-KQGICBIGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical compound C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical class CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DUEQXINXCBIZDH-UHFFFAOYSA-N ethanol;ethyl 6-amino-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-3-carboxylate Chemical compound CCO.C1=C2C(C(=O)OCC)=C(C=3C=CC(F)=CC=3)OC2=CC(N)=C1C1CC1 DUEQXINXCBIZDH-UHFFFAOYSA-N 0.000 description 1
- UNQUMGSSWNEUIM-UHFFFAOYSA-N ethyl 2-(4-bromopyridin-2-yl)acetate Chemical compound CCOC(=O)CC1=CC(Br)=CC=N1 UNQUMGSSWNEUIM-UHFFFAOYSA-N 0.000 description 1
- PCOIFIVNARQEPO-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-5-hydroxy-1-benzofuran-3-carboxylate Chemical compound O1C2=CC=C(O)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 PCOIFIVNARQEPO-UHFFFAOYSA-N 0.000 description 1
- JDTVYJUIRIKAMA-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitro-1-benzofuran-3-carboxylate Chemical compound O1C2=CC([N+]([O-])=O)=C(O)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 JDTVYJUIRIKAMA-UHFFFAOYSA-N 0.000 description 1
- GABVJHBTVTZBOQ-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-5-propan-2-yloxy-1-benzofuran-3-carboxylate Chemical compound O1C2=CC=C(OC(C)C)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 GABVJHBTVTZBOQ-UHFFFAOYSA-N 0.000 description 1
- YLLYHDZQPHLAEX-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)-1-benzofuran-3-carboxylate Chemical compound O1C2=CC([N+]([O-])=O)=C(OS(=O)(=O)C(F)(F)F)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 YLLYHDZQPHLAEX-UHFFFAOYSA-N 0.000 description 1
- BHQFYUQLUYVORD-UHFFFAOYSA-N ethyl 2-(4-fluorophenyl)-6-nitro-5-propan-2-yloxy-1-benzofuran-3-carboxylate Chemical compound O1C2=CC([N+]([O-])=O)=C(OC(C)C)C=C2C(C(=O)OCC)=C1C1=CC=C(F)C=C1 BHQFYUQLUYVORD-UHFFFAOYSA-N 0.000 description 1
- OWFFTVVEZANQDO-UHFFFAOYSA-N ethyl 2-bromo-3-(4-methoxyphenyl)-3-oxopropanoate Chemical compound CCOC(=O)C(Br)C(=O)C1=CC=C(OC)C=C1 OWFFTVVEZANQDO-UHFFFAOYSA-N 0.000 description 1
- SJUXLKYJKQBZLM-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=C(F)C=C1 SJUXLKYJKQBZLM-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- RWVAGKWUSVWRCX-UHFFFAOYSA-N ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-(methanesulfonamido)-1-benzofuran-3-carboxylate Chemical compound C1=C2C(C(=O)OCC)=C(C=3C=CC(F)=CC=3)OC2=CC(NS(C)(=O)=O)=C1C1CC1 RWVAGKWUSVWRCX-UHFFFAOYSA-N 0.000 description 1
- KQCGVJGECJGXRI-UHFFFAOYSA-N ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-nitro-1-benzofuran-3-carboxylate Chemical compound C1=C2C(C(=O)OCC)=C(C=3C=CC(F)=CC=3)OC2=CC([N+]([O-])=O)=C1C1CC1 KQCGVJGECJGXRI-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000004613 furo[2,3-c]pyridinyl group Chemical group O1C(=CC=2C1=CN=CC2)* 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000001553 hepatotropic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- KAGOEWVNTGUFGW-UHFFFAOYSA-N indolizine-1-carboxylic acid Chemical group C1=CC=CC2=C(C(=O)O)C=CN21 KAGOEWVNTGUFGW-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- BBFWUUBQSXVHHZ-UHFFFAOYSA-N methyl 3-oxo-1,2-oxazole-5-carboxylate Chemical compound COC(=O)C1=CC(=O)NO1 BBFWUUBQSXVHHZ-UHFFFAOYSA-N 0.000 description 1
- RONHWSHWVRBGFV-UHFFFAOYSA-N methyl 3-phenylmethoxy-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)=CC(OCC=2C=CC=CC=2)=N1 RONHWSHWVRBGFV-UHFFFAOYSA-N 0.000 description 1
- ZUVVLBGWTRIOFH-UHFFFAOYSA-N methyl 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate Chemical compound COC(=O)C(CC(C)C)NS(=O)(=O)C1=CC=C(C)C=C1 ZUVVLBGWTRIOFH-UHFFFAOYSA-N 0.000 description 1
- UPZJWNGFHFKIRM-UHFFFAOYSA-N methyl 6-[(4-methoxyphenyl)methyl-methylsulfonylamino]-2-phenyl-1-benzofuran-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=C(C=3C=CC=CC=3)OC2=CC=1N(S(C)(=O)=O)CC1=CC=C(OC)C=C1 UPZJWNGFHFKIRM-UHFFFAOYSA-N 0.000 description 1
- JFDAAXPEUBKECS-UHFFFAOYSA-N methyl 6-amino-2-phenyl-1-benzofuran-3-carboxylate Chemical compound O1C2=CC(N)=CC=C2C(C(=O)OC)=C1C1=CC=CC=C1 JFDAAXPEUBKECS-UHFFFAOYSA-N 0.000 description 1
- LUCOMIFDAFAJAU-UHFFFAOYSA-N methyl 6-nitro-2-phenyl-1-benzofuran-3-carboxylate Chemical compound O1C2=CC([N+]([O-])=O)=CC=C2C(C(=O)OC)=C1C1=CC=CC=C1 LUCOMIFDAFAJAU-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- GZQDQFTYTWSVCS-UHFFFAOYSA-N n-[3-cyano-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-6-yl]-n-(3-methylbutyl)methanesulfonamide Chemical compound CC(C)CCN(S(C)(=O)=O)C1=CC=2OC(C=3C=CC(F)=CC=3)=C(C#N)C=2C=C1C1CC1 GZQDQFTYTWSVCS-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000005063 oxadiazines Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical group CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000011949 solid catalyst Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical class C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 150000004867 thiadiazoles Chemical class 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical compound C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D88/00—Large containers
- B65D88/54—Large containers characterised by means facilitating filling or emptying
- B65D88/64—Large containers characterised by means facilitating filling or emptying preventing bridge formation
- B65D88/70—Large containers characterised by means facilitating filling or emptying preventing bridge formation using fluid jets
- B65D88/703—Air blowing devices, i.e. devices for the sudden introduction of compressed air into the container
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K31/00—Actuating devices; Operating means; Releasing devices
- F16K31/12—Actuating devices; Operating means; Releasing devices actuated by fluid
- F16K31/36—Actuating devices; Operating means; Releasing devices actuated by fluid in which fluid from the circuit is constantly supplied to the fluid motor
- F16K31/363—Actuating devices; Operating means; Releasing devices actuated by fluid in which fluid from the circuit is constantly supplied to the fluid motor the fluid acting on a piston
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/8593—Systems
- Y10T137/86389—Programmer or timer
- Y10T137/86405—Repeating cycle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T137/00—Fluid handling
- Y10T137/8593—Systems
- Y10T137/86389—Programmer or timer
- Y10T137/86405—Repeating cycle
- Y10T137/86421—Variable
Definitions
- This disclosure is directed to: (a) compounds and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
- HCV hepatitis C virus
- Hepatitis C is a blood-borne, infectious, viral disease that is caused by a hepatotropic virus called HCV.
- HCV genotypes At least six different HCV genotypes (with several subtypes within each genotype) are known to date.
- HCV genotype la predominates, followed by HCV genotypes lb, 2a, 2b, and 3a.
- HCV genotypes 1, 2, and 3 are the most common, with about 80% of the hepatitis C patients having HCV genotype 1.
- HCV genotype lb is predominant, followed by HCV genotypes 2a, 2b, 2c, and 3a.
- HCV genotypes 4 and 5 are found almost exclusively in Africa.
- the patient's HCV genotype is clinically important in determining the patient's potential response to therapy and the required duration of such therapy.
- HCV infection can cause liver inflammation (hepatitis) that is often asymptomatic, but ensuing chronic hepatitis can result in cirrhosis of the liver (fibrotic scarring of the liver), liver cancer, and/or liver failure.
- the World Health Organization estimates that about 170 million persons worldwide are chronically infected with HCV, and from about three to about four million persons are newly infected globally each year. According to the Centers for Disease Control and Prevention, about four million people in the United States are infected with HCV. Co-infection with the human immunodeficiency virus (HIV) is common, and rates of HCV infection among HIV positive populations are higher.
- HCV human immunodeficiency virus
- ribavirin does not effectively suppress HCV levels, but an interferon/ribavirin combination is more effective than interferon alone.
- hepatitis C is treated with a combination of pegylated interferon alpha and ribavirin for a period of 24 or 48 weeks, depending on the HCV genotype.
- the goal of treatment is sustained viral response—meaning that HCV is not measurable in the blood after therapy is completed.
- Current standard of care including interferon and ribavirin, is known to require as many as 24-48 weeks of treatment to achieve any sustained viral response, and cure rates (sustained viral response) from treatment with standard of care in HCV genotypes 2 and 3 is often insufficient and even less sufficient in those with HCV genotypes 1 and 4.
- Treatment may be physically demanding, particularly for those with prior history of drug or alcohol abuse, because both interferon and ribavirin have numerous side effects.
- Common interferon-associated side effects include flu-like symptoms, extreme fatigue, nausea, loss of appetite, thyroid problems, high blood sugar, hair loss, and skin reactions at the injection site.
- Possible serious interferon-associated side effects include psychoses (e.g., suicidal behavior), heart problems (e.g., heart attack, low blood pressure), other internal organ damage, blood problems (e.g., blood counts falling dangerously low), and new or worsening autoimmune disease (e.g., rheumatoid arthritis).
- Ribavirin-associated side effects include anemia, fatigue, irritability, skin rash, nasal stuffiness, sinusitis, and cough. Ribavirin can also cause birth defects, so pregnancy in female patients and female partners of male patients must be avoided during treatment and for six months afterward.
- R is formula (i), (ii), (iii), (iv), or (v);
- R la at each occurrence, is each independently hydrogen, halogen, G-C 3 alkyl, or Q-
- R lb is each independently hydrogen, halogen, G-C 3 alkyl, or Q- C 3 haloalkyl, wherein, optionally, two geminal R lb taken together are oxo;
- R lc is Ci-C 3 alkyl
- R 2 is Ci-Cioalkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl, C 2 -Ci 0 haloalkenyl, C 2 - Ciohaloalkynyl, or L 2A -G 2a ;
- L 2A is a bond, C 2 alkenylene, or C 2 alkynylene
- G 2a is C 6 -Ci 0 aryl or 5- to 10-membered heteroaiyl, wherein the aryl or heteroaryl is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of R 20 , L 2B -R 21 , G 2b and L 2B -G 2b ;
- L 2B and L 2C are each independently Ci-C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -
- R 20 is hydrogen, Ci-Ci 0 alkyl, C 2 -Cioalkenyl, C2-Cioalkynyl, Ci-Ciohaloalkyl, C 2 - Ciohaloalkenyl, C 2 -Ci 0 haloalkynyl, halogen, -N(R 2a )C(0)R 2b , -C(0)N(R 2a )(R 2b ), -0-R 2b , -C(0)R 2b , -OC(0)R 2b , -C0 2 H, -C0 2 R 2b , -N(R 2a )C(0)N(R 2a )(R 2b ), -S-R 2b , -S(0) 2 R 2b , -S(0)R 2b , -S0 2 N(R 2a )(R 2b ), -N(R 2a )(R 2b ), -N(R 2a )S
- R 2a is each independently hydrogen, Ci-C 6 alkyl, C]-C 6 haloalkyl, or C 3 -C 8 cycloalkyl, wherein the Cj-Cgcycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, G-Cjalkyl, and G-Cjhaloalkyl;
- R 2b is each independently hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci- Ciohaloalkyl, C 2 -Ci 0 haloalkenyl, C 2 -C 10 haloalkynyl, -L 2C -R 2c , G 2b or -L 2C -G 2b ;
- R 2c is -N(R 2d )C(0)R 2d , -C(0)N(R 2d )(R 2d ), -0-R 2d , -C(0)R 2d , -OC(0)R 2d , -C0 2 H, -C0 2 R 2d , -N(R 2d )C(0)N(R 2d )(R 2d ), -S-R 2d , -S(0) 2 R 2d , -S(0)R 2d , -S0 2 N(R 2d )(R 2d ), -N(R 2d )(R 2d ), -N(R 2d )S(0) 2 R 2d , or N(R 2d )C(0)0(R d );
- R 2d is each independently hydrogen, G-C 6 alkyl, G-C 6 haloalkyl, Ci-C 6 alkylene-OH, or C 3 -C 8 cycloalkyl, wherein the C 3 -C 8 cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, G-C 3 alkyl, and G- C 3 haloalkyl; G is C3-Ciocycloalkyl, C 5 -Ciocycloalkenyl, C6-Cioaryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-Cioalkyl, C2-Ci 0 alkenyl, C 2 -Ci 0 alkynyl, C Ciohaloalkyl, C 2
- G 2c is C 6 -Ci 0 aryl or 5- to 10-membered heteroaryl, wherein G 2c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-Ci 0 alkyl, C 2 - Cioalkenyl, C 2 -Ci 0 alkynyl, Ci -Ciohaloalkyl, C 2 -Ci 0 haloalkenyl, C 2 -Ci 0 haloalkynyl, halogen, oxo, cyano, hydroxy, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, -Ci-C 3 alkylene-0-H, -Ci-C 3 alkylene-0-Ci- Cgalkyl, C(0)H, -C C 3 alkylene-NH 2 , -NH 2 , -N0 2 , -C(0)Ci-C 6 alkyl, and
- V 1 and V 2 are each C, or one of V 1 and V 2 is N and the other is C, wherein, when V 3 is N, O or S or when A is (vii), V 2 is C;
- V 3 is CR 7 , NR 7 , N, O, or S; or, when A is (vii), V 3 is N;
- R 7 is hydrogen, Ci-C 3 alkyl, Ci-C 3 haloalkyl, or C 3 -C 6 cycloalkyl;
- W 1 is N or CR 6
- W 2 is N or CR 5
- W 3 is N or CR 4
- W 4 is N or CR 3 , wherein none, one or two of W 1 , W 2 , W 3 and W 4 is N;
- W 5 is N or CR 6
- W 6 is N or CR 5 , wherein none or one of W 5 and W 6 is N;
- W 7 is N, O, or S
- R 3 and R 6 are each independently hydrogen, Ci-C 3 alkyl, Ci-C 3 haloalkyl, halogen, -OC C 3 alkyl, or -OCi-C 3 haloalkyl;
- R 4 is hydrogen, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, cyano, -NH 2 , L 4A -OH, 5-membered heteroaryl optionally substituted with 1 or 2 alkyl or halogen, 5- membered heterocycle or -N(R 40 )(SO 2 R 4a );
- R 40 is hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Cioalkynyl, Ci-Ciohaloalkyl, C 2 - Ciohaloalkenyl, C 2 -Ciohaloalkynyl, C 3 -Cscycloalkyl, 3- to 8-membered heterocyclyl, -L 4A -G 4a , -L 4A -C(0)-L 4B -G 4a , -L 4A -0-L 4B -G 4a , -L 4A -S(0) 2 -L 4B -G 4a , -L 4A -N(R 4b )(L 4B -G 4a ), -L 4A -N(R 4b )C(0)-L 4B -G 4a , -L 4A -N(R 4b )S(0) 2 -L 4B -G 4
- L 4A is Ci-Cioalkylene, C 2 -Ci 0 alkenylene, or C 2 -Cioalkynylene, wherein L 4A is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, d-dalkyl, and d-dhaloalkyl;
- G 4a is C 3 -Ci 2 cycloalkyl, C 6 -Ci 2 aryl, 3- to 12-membered heterocyclyl, or 5- to 12- membered heteroaryl, wherein G 4a is optionally substituted with L 4C -G 4b and optionally substituted with 1 , 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, C 3 haloalkyl, -OH, -0-C C 3 alkyl, -0-C C 3 haloalkyl, thioxo, -NH 2 , -NH(C C 3 alkyl), and -N(C C 3 alkyl) 2 ;
- L 4B and L 4C are each independently a bond, d-dalkylene, C 2 - C 6 alkenylene, or C 2 -C 6 alkynylene, wherein L 4B and L 4C are each optionally substituted with 1 , 2, 3, 4, or 5 substituents selected from the group consisting of halogen, d-dalkyl, and d-dhaloalkyl;
- G 4b is C 3 -Ci 2 cycloalkyl, 3- to 12-membered heterocyclyl, C 6 -Ci 2 aryl, or 5- to 12- membered heteroaryl, wherein G 4b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, d-dalkyl, d-dhaloalkyl, hydroxy, -0-Ci-C 6 alkyl, -O-Ci-Cehaloalkyl, -S(0)-C C 6 alkyl, -S(0) 2 -C C 6 alkyl, -C(0)-Ci-C 6 alkyl, C C 3 alkylene-OH, C C 3 alkylene-0-Ci-C 3 alkyl, Ci-C 3 alkylene-N(C C 3 alkyl) 2 , and Ci-C 3 alkylene-(N-heterocyclyl);
- R 4a and R 4b are each independently hydrogen, d-dalkyl, Ci- C 6 haloalkyl, or C 3 -C 8 cycloalkyl, wherein the C 3 -C 8 cycloalkyl is optionally substituted with 1 , 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, and Ci-C 3 haloalkyl;
- R 4c is -0-R 4b , -OC(0)R 4b , -0-Si(Ci-C 6 alkyl) 3 , -CN, -C(0)R 4b , -C0 2 R 4b , -C(0)N(R 4b ) 2 , -C(0)N(R 4b )S(0) 2 R 4b , -S-R 4b , -S(0) 2 R 4b , -S(0)R 4b , -S0 2 N(R 4b ) 2 , -N(R 4b ) 2 , -N(R 4b )C(0)R 4b ,
- R 5 is hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, C 3 -C 6 cycloalkyl, -0-C C 6 alkyl, -O-d- C 6 haloalkyl, -0-C 3 -C 6 cycloalkyl, or G 5a , wherein the C 3 -C 6 cycloalkyl groups are optionally substituted with 1 , 2, 3, or 4 substituents selected from the group consisting of halogen, Ci-C 3 alkyl, Ci-C 3 haloalkyl, and oxo;
- G 5a is phenyl, wherein G 5a is substituted with -C(0)N(R 5a )-L 5B -G 5b , -C(0)-G 5f , or -C(0)N(R 5a )(R 5e ), and optionally substituted with 1 , 2, or 3 substituents selected from the group consisting of Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ci 0 haloalkyl, halogen, -0-R 5b , CN, -N(R 5b )C(0)R 5b , -C(0)N(R 5a )(R 5b ), -C(0)R 5b , -OC(0)R 5b , -C0 2 H, -C0 2 R 5b , -N(R 5b )C(0)N(R 5a )(R 5b ), -S-R 5b
- G 5b is C 3 -Ci 2 cycloalkyl, C 6 -C ]2 aryl, 3- to 12-membered heterocyclyl, or 5- to 12- membered heteroaryl, wherein each G 5b is optionally substituted with 1 , 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, C r C 6 alkyl, C C 6 haloalkyl, -0-R 5d , -CN, -N(R 5d )C(0)R 5d , -CON(R 5a )(R 5d ), -C(0)R 5d , -OC(0)R 5d , -C0 2 H, -C0 2 R 5d , -N(R 5d )C(0)N(R 5d ) 2 , -S- R 5d , -S(0) 2 R 5d , -S(0)R 5d , -S0 2 N(R 5a )(R 5d
- G 5C is each independently CrQcycloalkyl, Ce-Qo ryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -O-Ci- C 6 alkyl, and -0-Ci-C 6 haloalkyl;
- G 5d is each independently CrCscycloalkyl, C6-Cioaryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5d is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, Q-Ce lkyl, Q-Cehaloalkyl, -0-R 5d , -CN, -N(R 5d )C(0)R 5d , -CON(R 5a )(R 5d ), -C(0)R 5d , -OC(0)R 5d , -C0 2 H, -C0 2 R 5d , -N(R 5d )C(0)N(R 5d ) 2 , -S-R 5d , -S(0) 2 R 5d , -S(0)R 5d , -S0 2 N(R 5a )(R 5d ), -N(R 5a
- R 5a is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or C 3 -Cgcycloalkyl, wherein the C 3 -Cscycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, and Ci-C 3 haloalkyl;
- R 5b is each independently hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci- dohaloalkyl, -L 5D -G 5e , or -L 5G -R 5c ;
- R 5c is each independently -CON(R a )(R 3 ⁇ 4 ), -0-R g , -OC(0)R g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 , -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5d is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or -L 5F -G 5c ;
- R 5e is each independently hydrogen, Ci-Cioalkyl, C 2 -Cioalkenyl, C 2 -Cioalkynyl, Ci- Ciohaloalkyl, or -L 5E -R 5f ;
- R 5f is -CON(R 5a )(R 5d ), -0-R 5d , -OC(0)R 5d , -CN, -C(0)R 5d , -C0 2 H, -C0 2 R 5d , -N(R 5d )C(0)N(R 5d ) 2 , -S-R 5d , -S(0) 2 R 5d , -S(0)R 5d , -S0 2 N(R 5a )(R 5d ), -N(R 5a )(R 5d ), -N(R 5d )C(0)R 5d , or -N(R 5d )S(0) 2 R 5d ;
- R 5g is hydrogen, C C 6 alkyl, d-Cghaloalkyl, or -L 5H -G 5e ;
- G 5e is each independently Cj-Cgcycloalkyl, Cg-Cioaryl, 4- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Q-Cealkyl, Ci-C 6 haloalkyl, -OH, -0-Ci-C 6 alkyl, and -0-Ci-C 6 haloalkyl;
- G 5f is 4- to 10-membered heterocyclyl, wherein G 5f is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, and -O-d-Cghaloalkyl;
- L 5A at each occuiTence, is each independently Ci-C 6 alkylene or C 3 -C 8 cycloalkyl, wherein L 5A is each optionally substituted with 1, 2, 3, or 4 halogen;
- L 5B is a bond, Ci-Cealkylene, or Cj-Cgcycloalkyl, wherein L 5B is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5C is each independently Ci-C 6 alkylene or C 3 -C 8 cycloalkyl, wherein L 5C is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5D is each independently a bond, Cj-Cealkylene, or C3- Cgcycloalkyl, wherein L 5D is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5E is each independently Ci-Cealkylene, wherein L 5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently bond or Q-Cealkylene, wherein L 5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5G is each independently Q-Cealkylene, wherein L 5G is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5H is each independently a bond, Ci-Cgalkylene, or C3- C 8 cycloalkyl, wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.
- compositions comprising therapeutically effective amount of one or more compound(s) described herein or pharmaceutically acceptable salts, solvates, or salts of solvates thereof, in combination with one or more pharmaceutically acceptable carrier(s).
- compositions including pharmaceutical compositions that comprise one or more of the disclosed compounds and/or salts, and, optionally, one or more additional therapeutic agents.
- kits that comprise one or more compounds and/or salts of the disclosure, and, optionally, one or more additional therapeutic agents.
- This disclosure also is directed to methods of use of the compounds, salts, compositions, and/or kits to, for example, inhibit replication of an RNA virus (including HCV), treat a disease treatable by inhibiting HCV ribonucleic acid (RNA) polymerase (including hepatitis C).
- This disclosure also is directed to a use of one or more of the disclosed compounds and/or salts to prepare a medicament.
- the medicament optionally can comprise one or more additional therapeutic agents.
- the medicament is useful for treating hepatitis C.
- kits that comprise one or more of the disclosed compounds and/or salts, and, optionally, one or more additional therapeutic agents.
- compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
- compounds described herein may contain variables that occur more than one time in any substituent or in the compound described or any other formulae herein.
- Stable compounds are compounds that can be isolated from a reaction mixture.
- C 3 alkyl refers to an alkyl group of three carbons
- Ci-C 3 alkyl refers to an alkyl group that may have from one to three carbon atoms
- Ci-C 6 alkylene refers to an alkylene group of from one to six carbons
- alkenyl as used herein, means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond.
- C 2 -Ci 0 alkenyl means an alkenyl group containing 2-10 carbon atoms.
- Non-limiting examples of alkenyl include buta-2,3-dienyl, ethenyl, 2- propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
- alkenylene means a divalent group derived from a straight or branched chain hydrocarbon and contains at least one carbon-carbon double.
- C 2 -C 6 alkenylene means an alkenylene group containing 2-6 carbon atoms.
- alkoxy as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
- Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
- alkyl as used herein, means a straight or branched, saturated hydrocarbon chain.
- Ci-Cio alkyl means a straight or branched chain, saturated hydrocarbon containing 1 to 10 carbon atoms.
- C1-C3 alkyl means a straight or branched chain, saturated hydrocarbon containing 1 to 3 carbon atoms.
- alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n- nonyl, and n-decyl.
- alkylene means a divalent group derived from a straight or branched, saturated hydrocarbon chain. Examples of alkylene include, but are not limited to, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, -CH(C3 ⁇ 4)-, and -CH 2 CH(C3 ⁇ 4)CH 2 -.
- alkynyl as used herein, means a straight or branched chain hydrocarbon group containing at least one carbon-carbon triple bond.
- C 2 -Cio alkynyl means an alkynyl group containing from 2 to 10 carbon atoms. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
- aryl as used herein, means phenyl or a bicyclic aryl.
- C6-Cioaryl refers to an aryl group that may have from six to ten carbon atoms.
- the bicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl, or a phenyl fused to a monocyclic cycloalkenyl.
- Non- limiting examples of the aryl groups include dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl.
- the aryl groups can be unsubstituted or substituted, and the bicyclic aryl is attached to the parent molecular moiety through any substitutable carbon atom contained within the bicyclic ring system.
- cyano as used herein, means a -CN group.
- cycloalkyl or "cycloalkane” as used herein, means a monocyclic, a bicyclic, or a tricyclic cycloalkyl.
- the monocyclic cycloalkyl is a carbocyclic ring system containing three to eight carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- the bicyclic cycloalkyl is a monocyclic cycloalkyl fused to a monocyclic cycloalkyl ring.
- Tricyclic cycloalkyls are exemplified by a bicyclic cycloalkyl fused to a monocyclic cycloalkyl.
- the monocyclic or bicyclic cycloalkyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
- bridged cycloalkyl ring systems include bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.0 ' 7 ]nonane (octahydro-2,5-methanopentalene or noradamantane), and
- the monocyclic, bicyclic, and tricyclic cycloalkyls can be unsubstituted or substituted, and are attached to the parent molecular moiety through any substitutable atom contained within the ring system.
- cycloalkenyl or "cycloalkene” as used herein, means a monocyclic or a bicyclic hydrocarbon ring system.
- the monocyclic cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms and zero heteroatoms.
- the four-membered ring systems have one double bond, the five-or six- membered ring systems have one or two double bonds, and the seven- or eight-membered ring systems have one, two, or three double bonds.
- monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
- the bicyclic cycloalkenyl is a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, or a monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group.
- the monocyclic or bicyclic cycloalkenyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system.
- Representative examples of the bicyclic cycloalkenyl groups include, but are not limited to, 4,5,6,7- tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene.
- the monocyclic and bicyclic cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems, and can be unsubstituted or substituted.
- halo or halogen as used herein, means CI, Br, I, or F.
- haloalkyl as used herein, means an alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen.
- Ci-Ciohaloalkyl means a Ci-Cio alkyl group, as defined herein, in which one, two, three, four, five or six hydrogen atoms are replaced by halogen.
- haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, 2- chloro-3-fluoropentyl, trifluorobutyl (such as, but not limited to, 4,4,4-trifluorobutyl), and trifluoropropyl (such as, but not limited thereto, 3,3,3-trifluoropropyl).
- haloalkenyl refers to an alkenyl group, as defined herein, substituted by one, two, three, or four halogen atoms.
- haloalkynyl refers to an alkynyl group, as defined herein, substituted by one, two, three, or four halogen atoms.
- heterocycle means a monocyclic heterocycle, a bicyclic heterocycle, or a tricyclic heterocycle.
- the monocyclic heterocycle is a three-, four-, five-, six-, seven-, or eight-member ed ring containing at least one heteroatom independently selected from the group consisting of O, N, and S.
- the three- or four-membered ring contains zero or one double bond and one heteroatom selected from the group consisting of O, N, and S.
- the five- membered ring contains zero or one double bond and one, two, or three heteroatoms selected from the group consisting of O, N, and S.
- the six-membered ring contains zero, one, or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S.
- the seven- and eight-membered rings contain zero, one, two, or three double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S.
- Non-limiting examples of monocyclic heterocycles include azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl (including, but not limited thereto, pyrrolidin-l-yl,
- the bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl group, or a monocyclic heterocycle fused to a monocyclic cycloalkyl, or a monocyclic heterocycle fused to a monocyclic cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic heterocycle.
- bicyclic heterocycles include benzopyranyl, benzothiopyranyl, 2,3-dihydrobenzofuranyl, 2,3- dihydrobenzothienyl, benzo[i/][l,3]dioxolyl and 2,3-dihydro-lH-indolyl.
- Tricyclic heterocycles are exemplified by a bicyclic heterocycle fused to a phenyl group, or a bicyclic heterocycle fused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to a monocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclic heterocycle.
- the monocyclic and the bicyclic heterocycles may contain an alkenylene bridge of two, three, or four carbon atoms, or one or two alkylene bridges of 1, 2, 3, or 4 carbon atoms, or combinations thereof, wherein each bridge links two non-adjacent atoms of the ring system.
- bridged heterocycles include octahydro-2,5- epoxypentalene, azabicyclo[2.2.1]heptyl (including 2-azabicyclo[2.2.1]hept-2-yl), hexahydro-2 f-2,5- methanocyclopenta[6]furan, hexahydro-l/f-l,4-methanocyclopenta[c]furan, aza-admantane
- the monocyclic, bicyclic, and tricyclic heterocycles can be unsubstituted or substituted, and are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings.
- the nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quaternized.
- N- heterocyclyl refers to a nitrogen-containing heterocyclic group attached to the parent molecular moiety through a nitrogen atom.
- heteroaryl as used herein, means a monocyclic heteroaryl or a bicyclic heteroaryl.
- the monocyclic heteroaryl is a five- or six-membered ring.
- the five-membered ring contains two double bonds.
- the five membered ring may contain one heteroatom selected from O or S; or one, two, three, or four nitrogen atoms and optionally one oxygen or one sulfur atom.
- the six-membered ring contains three double bonds and one, two, three or four nitrogen atoms.
- monocyclic heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-l-yl), isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g.
- pyridin-4-yl pyridin-2-yl, pyridin-3-yl
- pyridazinyl pyrimidinyl
- pyrazinyl pyrazolyl
- pyrrolyl tetrazolyl
- thiadiazolyl 1,3-thiazolyl
- thienyl including, but not limited thereto, thien-2-yl, thien-3-yl
- triazolyl including, but not limited thereto, thien-2-yl, thien-3-yl
- triazolyl triazinyl.
- the bicyclic heteroaryl consists of a monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclic heteroaryl fused to a monocyclic heterocycle.
- bicyclic heteroaryl groups include benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, 6,7-dihydro-l,3-benzothiazolyl, furo[3,2- c]pyridazinyl, furo[3,2-J]pyrimidinyl, furo[2,3-6]pyrazinyl, furo[2,3-c]pyridazinyl, furo[2,3- i/]pyrimidinyl, furo[3,2-6]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, furo[2,3-6]pyridine, imidazo [2, 1 -b]oxazolyl, imidazo [ 1 ,2-a]pyridinyl, imidazo [2, 1 -b] [ 1 ,3,4]thiadiazolyl, imidazo[2, 1 - £>
- the monocyclic and bicyclic heteroaryl groups can be substituted or unsubstituted and are connected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the ring systems.
- heteroatom as used herein, means a nitrogen, oxygen, or sulfur atom.
- hydroxyl or "hydroxy” means a -OH group.
- a substituent is "substitutable" if it comprises at least one carbon or nitrogen atom that is bonded to one or more hydrogen atoms.
- hydrogen, halogen, and cyano do not fall within this definition.
- a sulfur atom in a heterocyclyl containing such atom is substitutable with one or two oxo substituents.
- a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent.
- a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent.
- monofluoroalkyl is alkyl substituted with a fluoro radical
- difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there is more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).
- substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions.
- tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non- hydrogen radical.
- an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.
- haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical.
- haloalkyls include chloromethyl, 1 -bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
- perhalo indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, i.e., each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term “perfluoro” means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term “perfluoroalkyl” means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.
- alkylcycloalkyl contains two components: alkyl and cycloalkyl.
- the Ci-C 6 - prefix on Ci-C6-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the Ci-C 6 -prefix does not describe the cycloalkyl component.
- the prefix "halo" on haloalkoxyalkyl indicates that only the alkoxy component of the alkoxyalkyl substituent is substituted with one or more halogen radicals.
- halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as "halogen-substituted alkoxyalkyl” rather than “haloalkoxyalkyl.” And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as "alkoxyhaloalkyl.”
- each substituent is selected independent of the other.
- Each substituent therefore, may be identical to or different from the other substituent(s).
- the rightmost-described component of the substituent is the component that has the free valence.
- the leftmost dash of the substituent indicates the portion of the substituent that is bound to the left element in the depicted structure.
- the rightmost dash indicates the portion of the substituent that is bound to the right element in the depicted structure.
- variable groups in compounds of formula (I) are as follows. Such values may be used where appropriate with any of the other values, definitions, claims or embodiments defined herein.
- R 1 may be formula (i), (ii), (iii), (iv) or (v).
- R 1 is (i), wherein R la is as defined herein.
- R la is hydrogen, Ci-C 3 alkyl (e.g., methyl), Ci- C 3 haloalkyl (e.g., trifluoromethyl), or halogen (e.g., fluoro, chloro, bromo).
- one R la is methyl; for example, where one R a is methyl and the other R a is hydrogen.
- both R la are methyl.
- both R la are hydrogen.
- R 1 is (ii), wherein R lb is as defined herein.
- R 1 is (ii), wherein R lb is as defined herein.
- R lb is hydrogen, d-C 3 alkyl (e.g., methyl), d-C 3 haloalkyl (e.g., trifluoromethyl), or halogen (e.g., fluoro), where two geminal R lb taken together optionally are oxo, as in formula (ii-1).
- R lb are each hydrogen.
- R 1 is (iii), wherein R lb is as defined herein.
- R 1 is (iii), wherein R lb is as defined herein.
- R lb is hydrogen, d-C 3 alkyl (e.g., methyl, ethyl, propyl), Ci-Cshaloalkyl (e.g., trifluoromethyl), or halogen (e.g., fluoro), or two geminal R lb taken together are oxo, as in formula (iii- 1 ).
- one R lb is methyl, ethyl, or propyl and the other R lb is hydrogen.
- both R lb are methyl. In certain embodimen both R lb are hydrogen.
- R 1 is (iv), wherein R lc is as defined herein.
- R 1 is (iv), wherein R lc is as defined herein.
- R lc is methyl
- R 1 is (v), wherein R la is as defined herein.
- R 1 is (v), wherein R la is as defined herein.
- R la is hydrogen
- R 2 may be Ci-Cioalkyl, C2-Cioalkenyl, C2-Cioalkynyl, Ci-Ciohaloalkyl, C2-Ciohaloalkenyl, C 2 - Ciohaloalkynyl, or L 2A -G 2a , wherein L 2A and G 2a are as described herein.
- R 2 is L 2A -G 2a where L 2A is a bond and G 2a is optionally substituted C6-Ci 0 aryl or 5- to 10-membered heteroaryl.
- G 2a is phenyl substituted with R 20 where R 20 is halogen (e.g., fluoro, chloro); Ci-Cioalkyl; C 2 -Ci 0 alkenyl (e.g., hex-l-enyl); C 2 - Ci 0 alkynyl; Ci-Ciohaloalkyl; C 2 -Ci 0 haloalkenyl; or C 2 -Ci 0 haloalkynyl.
- R 20 is halogen (e.g., fluoro, chloro); Ci-Cioalkyl; C 2 -Ci 0 alkenyl (e.g., hex-l-enyl); C 2 - Ci 0 alkynyl; Ci-Ciohaloalkyl; C 2 -Ci 0 haloalkenyl; or C 2 -Ci 0 haloalkynyl.
- G 2a is phenyl substituted in the 4-position with halogen (e.g., fluoro, chloro); Ci-Cioalkyl; C 2 -Ci 0 alkenyl (e.g., hex-l-enyl); C 2 -Ci 0 alkynyl; Ci-Ciohaloalkyl; C 2 - Ciohaloalkenyl; or C 2 -Ci 0 haloalkynyl.
- halogen e.g., fluoro, chloro
- Ci-Cioalkyl C 2 -Ci 0 alkenyl (e.g., hex-l-enyl); C 2 -Ci 0 alkynyl; Ci-Ciohaloalkyl; C 2 - Ciohaloalkenyl; or C 2 -Ci 0 haloalkynyl.
- G 2a is phenyl substituted with G 2b (i.e., R 2 is
- R 2 -I R 2 -I ) and G 2b is as defined herein.
- R 2 is R 2 -II,
- G 2b is phenyl, pyridyl, or thiophenyl where G is optionally substituted as described herein.
- G 2b can be substituted with halogen, hydroxy, cyano, nitro, Ci-Cioalkyl, -Q- C 3 alkylene-0-H, -0-C C 6 alkyl, Ci-Ciohaloalkyl, -C 1 -C 3 alkylene-0-C 1 -C 6 alkyl, C(0)H, -Q- C 3 alkylene-NH 2 , -NH 2 , -N0 2 , -C(0)Ci-C 6 alkyl or -C(0)OCi-C 6 alkyl.
- R 2 is R 2 -II, where G 2b is phenyl optionally substituted with halogen (e.g., fluoro, chloro), hydroxy, cyano, nitro, C r C 6 alkyl (e.g., methyl, ethyl, isopropyl), -Ci-C 3 alkylene-0-H (e.g., CH 2 OH), -0-Ci-C 3 alkyl (e.g., methoxy), Ci-C 6 haloalkyl (e.g., trifluoromethyl, trifluoroethyl, trifluorobutyl), -C
- halogen e.g., fluoro, chloro
- C r C 6 alkyl e.g., methyl, ethyl, isopropyl
- -Ci-C 3 alkylene-0-H e.g., CH 2 OH
- C 3 alkylene-0-Ci-C 3 alkyl e.g., CH 2 OCH 3
- C(0)H, -Ci-C 3 alkylene-NH 2 e.g., CH 2 NH 2
- -NH 2 e.g., -NH 2
- -C(0)OCi-C 3 alkyl e.g., C(O)OEt
- R 2 is R 2 -II and G 2b is pyridin-3-yl, optionally substituted with halogen (e.g., fluoro) or -0-Ci-C 3 alkyl (e.g., methoxy).
- G 2b includes, but is not limited to, 6-pyridin-3-yl, fluoropyridin-3-yl and 6-methoxypyridin-3-yl.
- R 2 is R 2 -II and G 2b is pyridin-4-yl optionally substituted with halogen (e.g., fluoro).
- G 2b includes, but is not limited to, pyridin-4-yl and 2-fluoropyridin-4-yl.
- R 2 is R 2 -II and G 2b is thiophen-2-yl.
- R is R -II and G is thiophen-3-yl, optionally substituted with C(0)H.
- G includes, but is not limited to, thiophen-3-yl and 2-formylthiophen-3-yl.
- R 2 is R 2 -II and G 2b is indol-5-yl
- R 2 is R 2 -II and G 2b is benzo[i/][l,3]dioxol-5-yl).
- R 2 is R 2 -II and G 2b is furan-2-yl.
- G 2a is phenyl substituted with G 2b (i.e., R 2 is
- R 2 is R 2 -II
- G is C 3 -Ci 0 cycloalkyl and 3- to 10-memembered heterocyclyl, where G is optionally substituted as described herein.
- G 2b can be substituted with halogen, hydroxy, cyano, nitro, Ci-Cioalkyl, -Ci-C 3 alkylene-0-H, -0-C C 6 alkyl, C Ci 0 haloalkyl, -Ci-C 3 alkylene-0-Ci- Cgalkyl, C(0)H, -Ci-C 3 alkylene-NH 2 , -NH 2 , -C(0)Ci-C 6 alkyl -C(0)OC C 6 alkyl, phenyl or pyridyl.
- R 2 is R 2 -II, where G 2b is cyclopropyl, pyrrolidinyl or mo holinyl optionally substituted with Ci-C 6 alkyl (e.g., methyl, ethyl, isopropyl), phenyl or pyridyl.
- G 2b is cyclopropyl, pyrrolidinyl or mo holinyl optionally substituted with Ci-C 6 alkyl (e.g., methyl, ethyl, isopropyl), phenyl or pyridyl.
- G 2a is phenyl substituted with R 20 (i.e., R 2 is
- R 2 is R 2 -IV.
- Embodiments according to R 2 -IV include compounds where R 20 is hydrogen, halogen (e.g., fluoro, chloro); Ci-Ci 0 alkyl (e.g., ethyl, butyl, n-hexyl, n-octyl); C 2 -Ci 0 alkenyl (e.g., but-l-enyl, hex- 1-enyl, oct-l-enyl); C 2 -Ci 0 alkynyl (e.g., but-l-ynyl, hex-l-ynyl, oct-l-ynyl); Ci-Ciohaloalkyl (e.g., trifluorobutyl, trifluorohexyl); C 2 -Ci 0 haloalkenyl; or C 2 -Ci 0 haloalkynyl.
- halogen e.g., fluor
- Embodiments according to R 2 -III and R 2 -IV include compounds where R 20 is -N(R 2a )(R 2b ); R 2a is hydrogen or Ci-C 3 alkyl (e.g., methyl); and R 2b is G 2b ; and G 2b is as defined herein.
- Particular embodiments according to R 2 -IV include compounds where R 20 is -N(H)(G 2b ), where G 2b is phenyl optionally substituted with halogen (e.g., fluoro, chloro), -O-Ci-Cjhaloalkyl (e.g., difluoromethoxy, trifluoromethoxy, trifluoroethoxy), cyano, or hydroxyl.
- halogen e.g., fluoro, chloro
- -O-Ci-Cjhaloalkyl e.g., difluoromethoxy, trifluoromethoxy, trifluoroethoxy
- G 2b includes, but is not limited to, 3,4-difluorophenyl, 3-chlorophenyl, pentafluorophenyl, 3-difluoromethoxyphenyl, 3-cyanophenyl, and 2,4-dichlorophenyl.
- Embodiments according to R 2 -III and R 2 -IV include compounds where R 20 is -N(R 2a )(R 2b ); R 2a is hydrogen or Ci-C 3 alkyl (e.g., methyl); and R 2b is G 2b ; and G 2b is as defined herein.
- R 2 -IV include compounds where R 20 is -N(H)(G 2b ), where G 2b is C 3 - Ciocycloalkyl optionally substituted with halogen (e.g., fluoro, chloro), -0-Ci-C 3 haloalkyl (e.g., difluoromethoxy, trifluoromethoxy, trifluoroethoxy), cyano, or hydroxyl.
- G 2b includes, but is not limited to, cyclopentyl and cyclohexyl.
- Embodiments according to R 2 -III and R 2 -IV include compounds where R 20 is -N(R 2a )(R b ); R 2a is hydrogen or Ci-C 3 alkyl (e.g., methyl); and R 2b is alkyl, Ci-C 10 haloalkyl or -L 2C -R 2c ; and L 2C and R 2c are as defined herein.
- L 2C is Ci-C 3 alkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 ) and R 2c is -O- R 2d , wherein R 2d is hydrogen, Ci-C 6 alkyl, or Ci-C 6 alkylene-OH.
- Embodiments according to R 2 -III and R 2 -IV include compounds where R 20 is -N(R 2a )(R 2b ); R 2a is hydrogen or d-C 3 alkyl (e.g., methyl); and R 2b is -L 2C -G 2b ; and L 2C and R 2c are as defined herein.
- L 2C is C C 3 alkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 ) and G 2b is C 3 -Ci 0 cycloalkyl, C 6 - Cioaryl, or 5- to 10-membered heteroaryl, wherein G 2b is optionally substituted with Ci-Cioalkyl, halogen, cyano, hydroxy, -0-Ci-C 6 alkyl, or -0-Ci-C 6 haloalkyl.
- Embodiments according to R 2 -IV include compounds where R 20 is -N(H)(G 2b ), where G 2b is C 3 -Ciocycloalkyl optionally substituted with halogen (e.g., fluoro, chloro), -0-Ci-C 3 haloalkyl (e.g., difluoromethoxy, trifluoromethoxy, trifluoroethoxy), cyano, or hydroxyl.
- G 2b includes, but is not limited to, cyclopentyl and cyclohexyl.
- Embodiments according to R 2 -IV include compounds where R 20 is -N(CH 3 )(G 2b ), where G 2b is phenyl optionally substituted.
- Embodiments according to R 2 -IV include compounds where R 20 is -N(H)(G 2b ), where G 2b is a 5- to 10-membered heteroaryl (e.g., indolyl).
- Embodiments according to R 2 -IV include compounds where R 20 is -0-R 2b , where R 2b is G b or -L 2c -G 2b , where L 2C is C 1 -C 3 alkylene (e.g., CH 2 ) and G 2b is as defined herein.
- R 2 -IV include compounds where R 20 is -O-L 2C -G 2b where L 2C is Ci-C 3 alkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 ) and G 2b is phenyl optionally substituted with halogen (e.g., fluoro, chloro), Ci-Cioalkyl (e.g., methyl, ethyl, f-butyl, hexyl), cyano, or -0-C]-C 3 haloalkyl (e.g., difluoromethoxy, trifluoromethoxy, trifluoroethoxy).
- L 2C Ci-C 3 alkylene
- G 2b is phenyl optionally substituted with halogen (e.g., fluoro, chloro), Ci-Cioal
- Embodiments according to R 2 -IV include compounds where R 20 is -O-G 2b or -O-L" ⁇ 1 -G J " ⁇ b where L 2C is Ci-C 3 alkylene (e.g., -CH 2 -) and G 2b is cycloalkyl (e.g., cyclopropyl, cyclobutyl) or cycloalkenyl (e.g., cyclohexenyl), wherein G 2b may be optionally substituted as defined herein.
- L 2C Ci-C 3 alkylene
- G 2b is cycloalkyl (e.g., cyclopropyl, cyclobutyl) or cycloalkenyl (e.g., cyclohexenyl), wherein G 2b may be optionally substituted as defined herein.
- Embodiments according to R 2 -IV include compounds where R 20 is -0-R 2b where R 2b is
- 2C 2c 2C hydrogen or Ci-Cioalkyl e.g., methyl, «-pentyl, isopentyl, isopropyl, w -hexyl
- L is Ci-Cealkylene (e.g., -C(CH 3 )(H)-, -(CH 2 ) 3 -) and R 2c is C0 2 (C C 3 alkyl) or -OC(0)Ci-C 3 alkyl.
- L 2A is a bond
- G 2a is phenyl substituted with L 2B -G 2b (i.e., R 2 is
- 2 is R 2 -VI.
- G 2a is phenyl substituted with L 2B -R 21 (i.e., R 2 is
- R 2 -VII In embodiments, 2 is R 2 -VII.
- Embodiments according to R 2 -VII and R 2 -VIII include compounds where L 2B is C r
- Cgalkylene (e.g., -CH 2 -, -CH(CH 3 ) 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -) and R 21 is is -N(R 2a )C(0)R 2b , -C(0)N(R 2a )(R 2b ), -0-R 2b , -C(0)R 2b , -OC(0)R 2b , -C0 2 H, -C0 2 R 2b , -N(R 2a )C(0)N(R 2a )(R 2b ), -S-R 2b , -S(0) 2 R 2b , -S(0)R 2b , -S0 2 N(R 2a )(R 2b ), -N(R 2a )(R 2b ), -N(R 2a )S(0) 2 R 2b , N(R 2a )C(0)0(R 2b ), or
- R 2a is hydrogen, d-Cgalkyl, C C 6 haloalkyl
- R 2b is hydrogen, d-Cioalkyl, C 2 -C ]0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl, or -L 2C -G 2b ; wherein - L 2C -G 2b is benzyl.
- R 2 is L 2A -G 2a where L 2A is C 2 alkynyl and G 2a is optionally substituted Q-Qoaryl or 5- to 10-membered heteroaryl.
- R 2 moieties are shown in Table 1 below.
- a and B together are a bicyclic heteroaryl.
- A is formula (vi) or formula (vii),
- W 1 , W 2 , W 3 , W 4 , W 5 , W 6 , and W 7 are as described herein, and B is
- V 1 , V 2 , V 3 , R 1 , and R 2 are as described herein, and is a single or double bond.
- a and B together are a bicyclic heteroaryl of formula (viii) or formula (ix):
- a and B together are a bicyclic heteroaryl of formula (viii), wherein W 1 , W 2 , V 2 , and V 3 are as described herein.
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 and V 2 are each C, and V 3 is NR 7 , 0, or S.
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 and V 2 are each C, and V 3 is NR 7 or O.
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 and V 2 are each C, and V 3 is O (i.e. benzofuranyl).
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 and V 2 are each C, and V 3 is NR 7 (i.e. indolyl).
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 is N, V 2 is C, and V 3 is CR 7 , NR 7 , N, O or S.
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 is N, V 2 is C, and V 3 is CR 7 (i.e. indolizinyl).
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 is C, V 2 is N, and V 3 is CR 7 , or N.
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 is C, V 2 is N, and V 3 is CR 7 (i.e. indolizinyl).
- W 1 , W 2 , W 3 , and W 4 are CR 6 , CR 5 , CR 4 , CR 3 , respectively; V 1 is C, V 2 is N, and V 3 is N (i.e. pyrazolo[l,5-a]pyridinyl).
- a and B together are bicyclic heteroaryl of formula (ix), wherein W 5 , W 6 , W 7 , V 1 , V 2 , and V 3 are as described herein.
- W 5 and W 6 are CR 6 and CR 5 , respectively; W 7 is O S; and V 1 is N, V 2 is C, and V 3 is N, O or S.
- W 5 and W 6 are CR 6 and CR 5 , respectively; W 7 is O; and V 1 is N, V 2 is C, and V 3 is N (i.e. imidazo[2,l-Z>]oxazolyl).
- W 5 and W 6 are CR 6 and CR 5 , respectively; W 7 is S; and V 1 is N, V 2 is C, and V ⁇ ' is N (i.e. imidazo[2,l -Z>]thiazolyl).
- R 3 may be hydrogen, Ci-C 3 alkyl, Q-Qhaloalkyl, halogen, -OQ-Qalkyl, or -OQ- C 3 haloalkyl. In certain embodiments, R 3 is hydrogen.
- R 6 may be hydrogen, Ci-C 3 alkyl, Ci-C 3 haloalkyl, halogen, -OCi-C 3 alkyl, or -OCi- C 3 haloalkyl.
- R 6 is halogen (e.g., fluoro, chloro).
- R 6 is hydrogen.
- R 7 may be hydrogen, Ci-C 3 alkyl, Ci-C 3 haloalkyl, or C 3 -C 6 cy cioalkyl. In certain embodiments, R 7 is hydrogen.
- R 4 may be hydrogen, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-C C 6 alkyl, -O-Q- C 6 haloalkyl, cyano, -NH 2 , L 4A -OH, 5 -membered heteroaryl optionally substituted with 1 or 2 alkyl halogen, 5 -membered heterocycle or -N(R 40 )(SO 2 R 4a ).
- R 4 is hydrogen.
- R 4 is -N(R 40 )(SO 2 R 4a ), where R 4a is Ci-C 3 alkyl (e.g., methyl, isopropyl).
- R 4 is CH 3 .
- R 40 is hydrogen; Ci-Cioalkyl (e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4-methylpentyl); C Cioalkyl substituted with 2 hydroxy substituents (e.g., 2,3-dihydroxypropyl, 3,4-dihydroxybutyl, 3,4- dihydroxy-4-methylpentyl); C 2 -Ci 0 alkenyl (e.g., allyl, 3-methylbut-2-enyl, 4-methylpent-3-enyl); C Ciohaloalkyl (e.g., 3-fluoropropyl, 3,3,3-trifluoropropyl, 4-fluorobutyl, 4,4,4-trif uorobutyl); or C 2 - Ciohaloalkeny
- Ci-Cioalkyl e.g., e
- R 4a is CH 3 ;
- R 40 is -L 4A -R 4c ;
- L 4A is C 2 -Ci 0 alkylene (e.g., CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , CH 2 C(H)(CH 3 ));
- R c is wherein R b is hydrogen or d-C 6 alkyl (e.g., methyl, propyl, pentyl); or R 4c is -0-Si(Ci-C 6 alkyl) 3 (e.g., -0-SiMe 2 t-Bu); or R 4c is -S-R 4b where R 4b is Ci-C 6 alkyl (e.g., methyl, propyl, pentyl); or R 4c is -N(R 4b ) 2 where R 4b is each independently hydrogen or Ci-C 6 alkyl (e.g., methyl, propyl, pentyl); or
- R 4c independently hydrogen or Ci-C 6 alkyl (e.g., CH 3 , CH 2 CH 3 ); or R 4c is -OC(0)R 4b , where R 4b is d- C 6 alkyl (e.g., CH 3 , CH 2 CH 3 ); or R 4c is -N(R 4b )C(0)R 4b , where each R 4b is independently hydrogen or Ci-Cealkyl (e.g., CH 3 , CH 2 CH 3 ).
- R 4a is CH 3 ;
- R 40 is -L 4A -R 4c ;
- L 4A is C Ci 0 alkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , 5-methylhexyl); and
- R 4c is cyano; or
- R 4c is -C(0)N(R 4b ) 2 , where R 4b is each independently hydrogen or CrC 6 alkyl (e.g., CH 3 , CH 2 CH 3 ); or
- R 4c is -C(0)N(R 4b )S(0) 2 R 4b , where R 4b is each independently hydrogen or C C 6 alkyl (e.g., CH 3 , CH 2 CH 3 ); or
- R 4c is -S(0)R 4b , where R 4b is Ci-C 6 alkyl (e.g., CH 3 , CH 2 CH 3 ); or R 4c is -S(0) 2 R 4b
- R 4 is -N(R 40 )(SO 2 R 4a ), where R 4a is C C 3 alkyl (e.g., CH 3 ) and R 40 is -L 4A -G 4a , where L 4A is Q-doalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 ) and G 4a is as defined herein.
- R 4a is CH 3
- L 4A is Ci-Ci 0 alkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 )
- G 4a is optionally substituted C 3 -Ci 2 cycloalkyl; C 6 -Ci 2 aryl; 3- to 12-membered heterocyclyl; or 5- to 12-membered heteroaryl.
- R 4a is CH 3
- L 4A is Ci-C 3 alkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 )
- G 4a is 5- to 6-membered heteroaryl substituted with L 4C -G 4b where L 4C is a bond and G 4b is optionally substituted C 6 -Ci 0 aryl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.
- L 4C is a bond
- G 4a -L 4C -G 4b is G 4a -G 4b .
- G 4a is C 3 -C 8 cycloalkyl (e.g., cyclopropyl, 2,2-difluorocycloprop-l-yl, cyclopentyl, cyclohexyl); C 6 - Cioaryl (e.g., phenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, naphthyl); 4- to 8-membered heterocyclyl (e.g., tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, 1,1-dioxotetrahydrothiephen- 3-yl, tetrahydropyran-4-yl, mo holin-4-yl, 5-thioxo-4,5-dihydro-l,2,4-oxadiazol-3-yl, 5-oxo-4,5- dihydro-l,2,4-oxadiazol-3-yl, 5-o
- G 4a is 5- to 6-membered heteroaryl optionally substituted with L 4C -G 4b where L 4C is a bond and G 4b is optionally substituted C6-Cioaryl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl.
- G 4a is thiazol-5-yl substituted in the 2-position with G 4b (i.e., ).
- G 4a -G 4b includes, but is not limited to, 2-(lH-indol-5-yl)thiazol-5-yl; 2-(l -methyl-l//-indol-5-yl)thiazol-5-yl; 2-(l//-indol-6-yl)thiazol-5- yl; 2-(l -pyrrolo[2,3-/j]pyridin-5-yl)thiazol-5-yl; 2-( l/ -indazol-5-yl)thiazol-5-yl; 2-(indolin-5- yl)thiazol-5-yl; 2-(2,3-dihydrobenzofuran-5-yl)thiazol-5-yl; 2-(2,5-dimethyl- l -pyrrol- l-yl)thiazol-4- yl; (2-(l f-benzo[d]imidazol-6-yl)thiazol-5-yl;
- R 4 is -N(R 40 )(SO 2 R 4a ), where R 4a is C C 3 alkyl (e.g., CH 3 ) and R 40 is -L 4A -S(0) 2 -L 4B -G 4a , where L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 ), L 4B is a bond, and G 4a is as defined here (i.e., R 40 is -L 4A -S(0) 2 -G 4a ).
- R 40 is -N(R 40 )(SO 2 R 4a ), where R 4a is C C 3 alkyl (e.g., CH 3 ) and R 40 is -L 4A -S(0) 2 -L 4B -G 4a , where L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2
- R 40 is -L 4A -S(0) 2 -G 4a and R 4a is CH 3
- L 4A is Ci-Ci 0 alkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 )
- G 4a is 4- to 8-membered heterocyclyl (e.g., morpholin-4-yl), or G 4a is C 6 -Cioaryl (e.g., phenyl, naphthyl), either optionally substituted.
- R 4 is -N(R 40 )(SO 2 R 4a ), where R 4a is C C 3 alkyl (e.g., CH 3 ) and R 40 is -L 4A -C(0)-L 4B -G 4a , where L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 ), L 4B is a bond, and G 4a is as defined herein (i.e., R 40 is -L 4A -C(0)-G 4a ).
- L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 ), and G 4a is 4- to 8-membered heterocyclyl (e.g., morpholin-4-yl, piperidin-l-yl), optionally substituted.
- R 4 is -N(R 40 )(SO 2 R 4a ), where R 4a is Ci-C 3 alkyl (e.g., CH 3 ) and R 40 is -L 4A -0-L 4B -G 4a , where L 4A is C r Ci 0 alkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 ), L 4B is a bond, and G 4a is as defined herein (i.e., R 40 is -L 4A -0-G 4a ).
- L 4A is C i -C h alky lene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 )
- G 4a is C 6 -Ci 0 aryl (e.g., phenyl, naphthyl), optionally substituted.
- R 5 may be hydrogen, Ci-C 6 alkyl (e.g., isopropyl, tert-butyl, ethyl), Ci-C 6 haloalkyl (e.g., trifiuoromethyl), C 3 -C 6 cycloalkyl (e.g., cyclopropyl), -0-Ci-C 6 alkyl (e.g., methoxy, isopropoxy), -O-Ci-Cehaloalkyl (e.g., trifluoromethoxy), -0-C 3 -C 6 cycloalkyl (e.g., -O-cyclopropyl), or G 5a , wherein the C -Cecycloalkyl groups are optionally substituted with 1 , 2, 3, or 4 substituents selected from the group consisting of halogen, Ci-C 3 alkyl, Q-Qhaloalkyl, and oxo; and G 5a is as defined herein.
- R 5 is hydrogen, Ci-Cealkyl (e.g., isopropyl, tert-butyl, ethyl), Ci- Cghaloalkyl (e.g., trifiuoromethyl), or -O-Ci-Cealkyl (e.g., methoxy, isopropoxy).
- R 5 is hydrogen, isopropyl, isopropoxy, or C3-C6Cycloalkyl (e.g., cyclopropyl).
- R 5 is cyclopropyl.
- R 5 is G 5a , where G 5a is phenyl substituted with -C(0)N(R 5a )-L 5B -G 5b , -C(0)-G 5f , or -C(0)N(R 5a )(R 5e ) and optionally substituted with 1, 2, or 3 substituents selected from the group consisting of Ci-Cioalkyl, C2-Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl. halogen, -0-R 5b , CN, and -G 5d ; wherein:
- G 5b is CrCncycloalkyl, C 6 -Ci2aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, wherein each G 5b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -O-R , -CN, -L 5L -0-R 5 , -L 5 -CN, and G 5c ;
- G 5d is each independently C 3 -C 8 cycloalkyl, C 6 -Ci 0 aryl, 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5d is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-R 5d , -CN, -N(R 5d )C(0)R 5d , -CON(R 5a )(R 5d ), -C(0)R 5d , -OC(0)R 5d , -C0 2 H, -C0 2 R 5d , -N(R 5d )C(0)N(R 5d ) 2 , -S- R 5d , -S(0) 2 R 5d , -S(0)R 5d , -S0 2 N(R 5a )(R 5d ),
- G 5c , G 5f , R 5a , R 5b , R 5d , R 5e , L 5B , and L 5C are as defined herein.
- the G 5a of R 5 is phenyl substituted in the meta position by the group -C(0)N(R 5a )-L 5B -G 5b as depicted in formula R 5 -I, and where R 5a , L 5B , and G 5b are as described herein and G 5a is further optionally substituted as described herein.
- G 5a may be further substituted by 1 , 2, or 3 additional substituents including, for example, Ci-C 6 alkyl (e.g., methyl, ethyl, isopropyl), Ci- Cehaloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), G 5d , or -0-R 5b :
- R 5a is hydrogen or methyl
- L 5B is d-Cealkylene (e.g., -CH 2 -, -C(CH 3 ) 2 - -C(CH 3 )(H)CH 2 - -C(CH 3 ) 2 CH 2 -), or C 3 - C 6 cycloalkyl (e.g., cyclopropyl, cyclobutyl);
- G 5b is C 3 -C 8 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl), C 6 -Ci 0 aiyl (e.g., phenyl, naphthyl, indanyl), 3- to 8-membered heterocyclyl (e.g., tetrahydrofuranyl, tetrahydropyranyl), or 5- to 10-membered heteroaryl (e.g., furanyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, triazolyl, oxadiazolyl, pyrazolyl, thienyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl), wherein each G 5b is optionally substituted with 1, 2, 3, 4, or 5
- Ci-Cealkyl e.g., methyl, ethyl, isopropyl
- d- C 3 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., hydroxy, methoxy
- -CN methoxymethyl, cyanomethyl, and G 5c ;
- G 5c is each independently cyclopropyl, phenyl, or 5- to 6-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), Ci- Cealkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -0-Ci-C 6 alkyl (e.g., methoxy), and -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- halogen e.g., fluoro, chloro
- Ci- Cealkyl e.g., methyl, ethyl
- Ci-C 6 haloalkyl e.g., triflu
- R 5b is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl), C 2 - C 6 alkenyl (e.g., allyl), C 2 -C 6 alkynyl (e.g., propargyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2- difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl,
- L 5D is each independently a bond, Ci-C 6 alkylene (e.g., -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- Ci-C 6 alkylene e.g., -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- L 5G is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 - -CH 2 CH(CH 3 )-);
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5g is independently, at each occurence, hydrogen, Ci-Cealkyl (e.g., methyl, ethyl), Ci- Cghaloalkyl (e.g., 2,2-difluoroethyl), or -L 5H -G 5e (e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl);
- L 5H is each independently bond or Ci-C 6 alkylene (e.g., -CH 2 -);
- G 5e is each independently C 3 -C 8 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl (e.g., ⁇ 1 ⁇ 1 ⁇ -4 ⁇ 1, pyrrolidin-l-yl, 4- methylpiperazin-l-yl, piperidinyl), or 5- to 10-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4- yl), wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C
- halogen
- G 5d is each independently C 3 -C 8 cycloalkyl, C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl (e.g., tetrahydropyrimidinyl), or 5- to 10-membered heteroaryl (e.g., furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, indolyl), wherein G 5d is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from the group consisting of oxo, halogen (e.g.
- Ci-C 6 alkyl e.g., methyl, ethyl, n-propyl, isopropyl
- Ci-C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., methoxy, ethoxy
- -CN e.g., -N(R 5d )C(0)R 5d (e.g., NHC(O)Me), -CON(R 5a )(R 5d ) (e.g., CONH 2 , CONHEt)
- -C(0)R 5d e.g., C(O)Me
- -OC(0)R 5d , -C0 2 H, -C0 2 R 5d (e.g., C0 2 Me), -N(R 5d )C(0)N(R 5d ) 2 (e.g., NHC(O)NHMe), -S-R 5d , -S(0) 2
- R 5d is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or -L 5F -
- L 5C is each independently Ci-C 6 alkylene (e.g., -CH 2 -) or C 3 -C 8 cycloaikyl (e.g., cyclopropyl); and
- L 5F is each independently bond or Ci-C 6 alkylene (e.g., -CH 2 -).
- Such embodiments may further include compounds where R 5a is hydrogen.
- Particular embodiments may include compounds where R 5 is R 5 -II, and
- L 5B is d-Cgalkylene (e.g., -CH 2 - -C(CH 3 ) 2 - -C(CH 3 )(H)CH 2 -, -C(CH 3 ) 2 CH 2 -) or C 3 - Cscycloalkyl (e.g., cyclopropyl, cyclobutyl);
- G 5b is C 3 -C 8 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl), C 6 -Ci 0 aryl (e.g., phenyl, naphthyl, indanyl), 3- to 8-membered heterocyclyl (e.g., tetrahydrofuranyl, tetrahydropyranyl), or 5- to 10-membered heteroaryl (e.g., furanyl, imidazolyl, thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, triazolyl, oxadiazolyl, pyrazolyl, thienyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl), wherein each G 5b is optionally substituted with 1, 2, 3, 4, or 5 substituent
- Ci-C 6 alkyl e.g., methyl, ethyl, isopropyl
- Ci- C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., hydroxy, methoxy
- -CN methoxymethyl
- G 5c is each independently cyclopropyl, phenyl, 5- to 6-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), Ci- C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -0-Ci-C 6 alkyl (e.
- halogen e.g., fluor
- R 50 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 51 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy), or G 5d ;
- G 5d is phenyl, tetrahydropyrimidinyl, furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, or indolyl;
- R 5b is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl), C 2 - Cealkenyl (e.g., allyl), C 2 -C 6 alkynyl (e.g., propargyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2- difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl,
- R 5c is -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g ) (e.g., NH 2 , N(CH 3
- R 5d is each independently hydrogen, Ci-C 6 alkyl, or Ci-C 6 haloalkyl
- R 5a is hydrogen or methyl.
- G 5b is phenyl or pyridinyl (e.g. pyridin-2-yl), wherein G 5b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g. fluoro), Ci-C 6 alkyl (e.g., methyl, ethyl, isopropyl), d-C 6 haloalkyl (e.g., trifluoromethyl), -0-R 5d (e.g., hydroxy, methoxy), and -CN.
- halogen e.g. fluoro
- Ci-C 6 alkyl e.g., methyl, ethyl, isopropyl
- d-C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., hydroxy, methoxy
- -CN e.g., hydroxy, methoxy
- Such embodiments may further include compounds where R 5a is hydrogen.
- the G 5a of R 5 is phenyl substituted in the meta position by the group -C(0)N(R 5a )(R 5e ) as depicted in formula R 5 -III, where R 5a and R 5e are as described herein and G 5a is further optionally substituted as described herein.
- Particular embodiments may include compounds where R 5 is R 5 -III wherein:
- G 5a is optionally substituted with additional substituents including, for example, Ci-C 6 alkyl
- Ci-Cehaloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- R 5a is hydrogen or methyl
- R 5e is hydrogen, Ci-Cioalkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Cioalkenyl, C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ciohaloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl), or -L 5E -R 5f (e.g., -C(CH 3 ) 2 -CONHMe, -C(CH 3 ) 2 -CONHCH 2 CHF 2 , -C(CH 3 ) 2 - C0 2 CH 3 , -C(CH 3 ) 2 CH 2 -C(0)CH 3 , -C(CH 3 ) 2 -CONH-thiazol-2-yl);
- R 5f is -CON(R 5a )(R 5d ) (e.g., CONHMe, CONHCH 2 CHF 2 , CONH-thiazol-2-yl), -0-R 5d (e.g., OMe), -CN, -C(0)R 5d (e.g., C(0)C3 ⁇ 4), -C0 2 H, -C0 2 R 5d (e.g., C0 2 CH 3 ), -N(R 5d )C(0)N(R 5d ) 2 , -S(0) 2 R 5d (e.g., S(0) 2 Me), -S(0)R 5d (e.g., S(O)Me), -S0 2 N(R 5a )(R 5d ) (e.g., S0 2 NH 2 , S0 2 NHEt), -N(R 5a )(R 5d ), -N(R 5d )C(0)R 5d (e.g., NHC(
- G 5d is each independently C 3 -C 8 cycloalkyl, C 6 -Ci 0 aryl (e.g., phenyl), 4- to 10-membered heterocyclyl (e.g., tetrahydropyrimidinyl), or 5- to 10-membered heteroaryl (e.g., furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, indolyl), wherein G 5d is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen (e.g.
- Ci-Cealkyl e.g., methyl, ethyl, n-propyl, isopropyl
- Ci-Cehaloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., methoxy, ethoxy
- -CN e.g., -N(R 5d )C(0)R 5d (e.g., NHC(O)Me), -CON(R 5a )(R 5d ) (e.g., CONH 2 , CONHEt)
- -C(0)R 5d e.g., C(O)Me
- -OC(0)R 5d , -C0 2 H, -C0 2 R 5d (e.g., C0 2 Me), -N(R 5d )C(0)N(R 5d ) 2 (e.g., NHC(O)NHMe), -S-R 5d , -S(0) 2 R
- R 5d is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci- Cehaloalkyl (e.g., 2,2-difluoroethyl), or -L 5F -G 5c (e.g., bond-thiazol-2-yl);
- G 5c is each independently CrCscycloalkyl (e.g., cyclopropyl), C6-Cioaryl (e.g., phenyl), 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), oxo, Ci-C 6 alkyl, Ci-C
- halogen e.g.,
- R 5b is each independently hydrogen, Ci-Ci 0 alkyl (e.g., methyl), C 2 - Ci 0 alkenyl (e.g., allyl), C 2 -Ci 0 alkynyl (e.g., propargyl), Ci-Ciohaloalkyl (e.g., trifluoromethyl, 2,2- difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl,
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5g is hydrogen, C C 6 alky
- G 5e is each independently C 3 -C 8 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl (e.g., ⁇ 1 ⁇ 1 ⁇ -4 ⁇ 1, pyrrolidin-l-yl, 4- methylpiperazin-l-yl, piperidinyl), or 5- to 10-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4- yl), wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C
- halogen
- L 5C is each independently Ci-Cealkylene or C 3 -Cscycloalkyl, wherein L 5C is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5D is each independently a bond, Ci-C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 8 cycloalkyl (e.g., cyclopropyl), and L 5D is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- Ci-C 6 alkylene e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 8 cycloalkyl e.g., cyclopropyl
- L 5E is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -), wherein L 5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently a bond or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -, -CH 2 CH(CH 3 )-), wherein L 5G is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy; and L , at each occurrence, is each independently a bond, or Ci-Cealkylene (e.g., -CH 2 -), wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.
- Such embodiments may further include compounds where R 5a is hydrogen.
- Particular embodiments may include compounds where R 5 is R 5 -IV, and
- R a is hydrogen or methyl
- R 5e is hydrogen, Ci-Cioalkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Cioalkenyl, C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ciohaloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl), or -L 5E -R 5f (e.g., -C(CH 3 ) 2 -CONHMe, -C(CH 3 ) 2 -CONHCH 2 CHF 2 , -C(CH 3 ) 2 - C0 2 CH 3 , -C(CH 3 ) 2 CH 2 -C(0)CH 3 , -C(CH 3 ) 2 -CONH-thiazol-2-yl);
- R 5f is -CON(R 5a )(R 5d ) (e.g., CONHMe, CONHCH 2 CHF 2 , CONH-thiazol-2-yl), -0-R 5d (e.g., OMe), -CN, -C(0)R 5d (e.g., C(0)C3 ⁇ 4), -C0 2 H, -C0 2 R 5d (e.g., C0 2 CH 3 ), -N(R 5d )C(0)N(R 5d ) 2 , -S(0) 2 R 5d (e.g., S(0) 2 Me), -S(0)R 5d (e.g., S(O)Me), -S0 2 N(R 5a )(R 5d ) (e.g., S0 2 NH 2 , S0 2 NHEt), -N(R 5a )(R 5d ), -N(R 5d )C(0)R 5d (e.g., NHC(
- R 5d is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci- Cehaloalkyl (e.g., 2,2-difluoroethyl), or -L 5F -G 5c (e.g., bond-thiazol-2-yl);
- Ci-C 6 alkyl e.g., methyl, ethyl
- Ci- Cehaloalkyl e.g., 2,2-difluoroethyl
- -L 5F -G 5c e.g., bond-thiazol-2-yl
- G 5c is each independently C 3 -C 8 cycloalkyl (e.g., cyclopropyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl (e.g., methoxy), and -0-Ci-C 6 haloalkyl;
- halogen e.g., fluoro, chloro
- oxo Ci-C 6 alkyl
- Ci-C 6 haloalkyl -
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-Ciohaloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-Ciohaloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-Ciohaloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- R 5b is hydrogen, Ci-C 6 alkyl (e.g., methyl), C 2 -C 6 alkenyl (e.g., allyl), C 2 -C 6 alkynyl (e.g., propargyl), C C 6 haloalkyl (e.g., trifluoromethyl, 2,2-difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl, -CH 2 -pyrrolidin-3-yl, -CH 2 CH 2 -mo holin-4-yl, -CH 2 CH 2 CH 2 -mo holin-4-yl, -CH 2 CH 2 -nK ⁇ holin-2-yl -CH 2 CH 2 -4-methylpiperazin- 1 -yl,
- G 5e is C 3 -C 6 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 7- membered heterocyclyl (e.g., mo holin-4-yl, pyrrolidin-l-yl, 4-methylpiperazin-l-yl, piperidinyl), or 5- to 6-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4-yl), wherein G 5e is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C 6 alkyl (e.g.,
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5g is, at each occurrence, independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Q- Cehaloalkyl (e.g., 2,2-difluoroethyl), or -L 5H -G 5e (e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl);
- L 5D is each independently a bond, Ci-C 6 alkylene (e.g., -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- Ci-C 6 alkylene e.g., -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- L 5E is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -), wherein L 5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently a bond or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -, -CH 2 CH(CH 3 )-); and
- L 5H is each independently a bond or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.
- R 5e is hydrogen, Ci-Ci 0 alkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Cioalkenyl, or C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ciohaloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl);
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy), or G 5d ;
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- G 5d is C 3 -C 8 cycloalkyl, C 6 -Cioaryl (e.g., phenyl), 4-to 10-membered heterocyclyl (e.g., tetrahydropyrimidinyl), or 5- to 10-membered heteroaryl (e.g., furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, indolyl), wherein G is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen (e.g.
- Ci-C 6 alkyl e.g., methyl, ethyl, n-propyl, isopropyl
- Ci-C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., methoxy, ethoxy
- -CN e.g., -N(R 5a )C(0)R 5d (e.g., NHC(O)Me)
- -CON(R 5a )(R 5d ) e.g., CONH 2 ,
- N(R 5a )C(0)0(R 5d ) e.g., NHC(O)OMe
- -L 5C -0-R 5d e.g., hydroxymethyl, methoxymethyl
- -L 5C -CN e.g., cyanomethyl
- G 5c e.g., phenyl
- -L 5C -G 5c e.g., benzyl
- R 5e is each independently hydrogen, Ci-Ci 0 alkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 -Ci 0 alkenyl, or C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ci 0 haloalkyl (e.g., 1,1,1 -trifluoro-2-methylpropan-2-yl);
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy); and
- R 5b is hydrogen, Ci-C 6 alkyl (e.g., methyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2- difluoroethyl), -L 5D -G 5e (e.g., bond-cyclopropyl, bond-cyclobutyl, -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl, -CH 2 -pyrrolidin-3-yl, - ⁇ 2 ⁇ 2 - ⁇ 1 ⁇ 1 ⁇ -4- ⁇ 1, -CH 2 CH 2 CH 2 -mo holin-4-yl, -CH 2 CH 2 -mo holin-2-yl -CH 2 CH 2 -4-methylpiperazin-l-yl, -CH 2 CH 2 -piperidinyl, -CH 2 -piperidin-3- yl, -CH 2 -pyridin-2-yl, -
- G 5e is C 3 -C 6 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4- to 7- membered heterocyclyl (e.g., ⁇ 1 ⁇ 1 ⁇ -4- ⁇ 1, pyrrolidin-l-yl, 4-methylpiperazin-l-yl, piperidinyl), or 5- to 6-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4-yl), wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci- Cgalkyl (e.g., methyl, ethyl), C C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C 6 alkyl (e.g.,
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ; R 5g is independently, at each occurrence,
- L 5D is a bond, C C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- C C 6 alkylene e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 - - C(CH 3 ) 2 CH 2 -, -CH 2 CH(CH 3 )-); and
- L 5H is each independently a bond, or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.
- W 1 is CR 6
- W 2 is CR 5
- W 3 is CR 4
- W 4 is CR 3
- V 1 is C
- V 2 is C and V 3 is O (i.e. benzofuranyl);
- R 1 is (i), (ii), (iii), (iv), or (v);
- R la at each occurrence, is each independently hydrogen, halogen, Ci-C 3 alkyl, or Ci- C 3 haloalkyl;
- R lb is each independently hydrogen, halogen, Ci-C 3 alkyl, or Ci- C 3 haloalkyl, wherein two geminal R lb taken together optionally are oxo;
- R lc is C 1 -C 3 alkyl
- R 2 is L 2A -G 2a ;
- L 2A is a bond
- G 2a is C 6 -Ci 0 aryl optionally substituted with a substituent selected from the group consisting
- R is hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ci 0 haloalkyl, C 2
- Ciohaloalk tceeinyl, C 2 -Ci 0 haloalkynyl, halogen, -N(R a )(R b ), -O-R , or -C( CH 2 )R 2b ;
- R 2a is hydrogen or Ci-C 3 alkyl
- R 2b is C doalkyl, L 2C -R 2c , G 2b , or -L 2C -G 2b ;
- L 2C is Ci-C 6 alkylene
- R 2c is C0 2 (Ci-C 3 alkyl) or -OC(0)Ci-C 3 alkyl;
- G 2b is C 3 -Ciocycloalkyl, C 5 -Ciocycloalkenyl, C 6 -Ci 0 aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl, C 2 - Ciohaloalkenyl, C 2 -Ci 0 haloalkynyl, halogen, oxo, cyano, hydroxy, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, -Ci-C 3 alkylene-0-H, -Ci-C 3 alkylene-0-C C 6 alkyl, C(0)H, -C C
- R 3 is hydrogen
- R 4 is -N(R 40 )(SO 2 R 4a ); R 4a is Ci-Cealkyl;
- R 40 is hydrogen, Ci-Ci 0 alkyl, Ci-Ci 0 alkyl substituted with 2 hydroxy substituents, C 2 - C 10 alkenyl, Q-dohaloalkyl, C 2 -C 10 haloalkenyl, -L 4A -R 4c , -L 4A -G 4a , -L 4A -S(0) 2 -G 4a , -L 4A -C(0)-G 4a , or -L 4A -0-G 4a ;
- L 4A is Ci-Ci 0 alkylene
- R 4c is -0-R 4b , -0-Si(C 1 -C 6 alkyl) 3 , -S-R 4b , -N(R 4b ) 2 , -N(R 4b )S(0) 2 R 4b , -OC(0)R 4b ,
- R 4b at each occurrence, is each independently hydrogen or Ci-C 6 alkyl
- G 4a is C 3 -Ci 2 cycloalkyl, C 6 -Ci 2 aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl wherein G 4a is optionally substituted with G 4b and optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, Ci-C 3 haloalkyl, -OH, -0-C C 3 alkyl, -0-C C 3 haloalkyl, thioxo, -NH 2 , -NH(C C 3 alkyl), and -N(C 1 -C 3 alkyl) 2 ;
- G 4b is C 3 -Ci 2 cycloalkyl, 3- to 12-membered heterocyclyl, C6-Ci 2 aryl, or 5- to 12-membered heteroaryl, wherein G 4b is optionally substituted with 1 , 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, d-C 6 alkyl, Ci-C 6 haloalkyl, hydroxy, -0-Ci-C 6 alkyl, -O-Ci- Cghaloalkyl, -S(0)-Ci-C 6 alkyl, -S(0) 2 -Ci-C 6 alkyl, -C(0)-C C 6 alkyl, Ci-C 3 alkylene-OH, C r
- Ci-C 3 alkylene-N(C C 3 alkyl) 2 Ci-C 3 alkylene-(N-heterocyclyl);
- R 5 is hydrogen, C 3 -C 6 cycloalkyl, or -0-Ci-C 6 alkyl
- R 6 is hydrogen or fluorine.
- Such embodiments may include compounds where R is R -II or R -IV, and G and R are as defined herein.
- Embodiments also include compounds of formula (I), wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is C and V 3 is O (i.e. benzofuranyl); and wherein R 1 is (i), (ii), (iii), or (v).
- Embodiments include compounds of formula (I) , wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is N, and V 3 is N (i.e. pyrazolo[l ,5-a]pyridinyl), wherein R 1 is (i), (ii), (iii), or (v).
- Such embodiments may include groups of compounds wherein:
- R la is each independently hydrogen, halogen (e.g., fluoro), Ci-C 3 alkyl (e.g., methyl), or Ci-C 3 haloalkyl (e.g., trifluoromethyl);
- halogen e.g., fluoro
- Ci-C 3 alkyl e.g., methyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- R lb is each independently hydrogen, halogen, or Ci-C 3 alkyl (e.g., methyl, ethyl, propyl), wherein two geminal R lb taken together optionally are oxo;
- R 2 is R 2 -II or R 2 -IV;
- R is hydrogen, halogen (e.g., fluoro), Ci-Cioalkyl (e.g., ethyl, butyl, n-hexyl, n-octyl), C 2 - Ci 0 alkenyl (e.g., but-l-enyl, hex-l-enyl, oct-l-enyl), C 2 -Ci 0 alkynyl (e.g., but-l-ynyl, hex-l-ynyl, oct- 1-ynyl), Ci-Ciohaloalkyl (e.g., trifluorobutyl, trifluorohexyl), C 2 -Ciohaloalkenyl, C 2 -Ci 0 haloalkynyl, -N(R 2a )(G 2b ), -0-
- R 2a is hydrogen or Ci-C 3 alkyl (e.g., methyl);
- G 2b is CrCiocycloalkyl (e.g., cyclopropyl, cyclobutyl), C 5 -Ci 0 cycloalkenyl (e.g., cyclohexenyl), C 6 -Ci 0 aryl (e.g., phenyl), 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridyl, thiophenyl, indolyl, benzo[d]oxadiazolyl), wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-C 6 alkyl (e.g., methyl, ethyl, t-butyl, hexyl), C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl (e.g., trifluoromethyl, trifluor
- L 2C is d-Cgalkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 , -(CH 2 ) 3 -);
- R 2c is C0 2 (Ci-C 3 alkyl) or -OC(0)Ci-C 3 alkyl;
- R 3 is hydrogen
- R 4 is -N(R 40 )(SO 2 R 4a );
- R 4a is Ci-C 3 alkyl (e.g., methyl);
- R 40 is hydrogen, Ci-Ci 0 alkyl (e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl), Ci-Ci 0 alkyl substituted with 2 hydroxy substituents (e.g., 2,3-dihydroxypropyl, 3,4- dihydroxybutyl, 3,4-dihydroxy-4-methylpentyl), C 2 -Ci 0 alkenyl (e.g., allyl, 3-methylbut-2-enyl, 4- methylpent-3-enyl), Ci-Ciohaloalkyl (e.g., 3-fluoropropyl, 3,3,3-trifluoropropyl, 4-fluorobutyl, 4,4,4- trifluorobutyl), C 2 -Ciohaloalkenyl (e.g., 5,6,6-trifluorohex-5-eny
- L 4A is d-doalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , CH 2 C(H)(CH 3 ), 5-methylhexyl);
- R 4c is -0-R 4b , -0-Si(C C 6 alkyl) 3 (e.g., -0-SiMe 2 t-Bu), -S-R 4b , -N(R 4b ) 2 , -N(R 4b )S(0) 2 R 4b , -OC(0)R 4b , -N(R 4b )C(0)R 4b , cyano, -C(0)N(R 4b ) 2 , -C(0)N(R 4b )S(0) 2 R 4b , -S(0)R 4b , -S(0) 2 R 4b , -S0 2 N(R 4b ) 2 , -C0 2 R 4b , -C(NOH)N(R 4b ) 2 , -C(0)R 4b , -C(0)C(OH)(R 4b ) 2 , or -P(0)(OR 4b ) 2 ;
- R 4b is each independently hydrogen or Ci-C 6 alkyl (e.g., methyl, ethyl, propyl, pentyl);
- G 4a is C 3 -C 8 cycloalkyl (e.g., cyclopropyl, 2,2-difluorocycloprop-l-yl, cyclopentyl, cyclohexyl), C 6 -Ci 0 aryl (e.g., phenyl, 4-methoxyphenyl, 3-trifluoromethylphenyl, naphthyl), 4- to 8- membered heterocyclyl (e.g., tetrahydrofuran-2-yl, pyrrolidin-l-yl, pyrrolidin-2-yl, 1,1- dioxotetrahydrothiephen-3-yl, tetrahydropyran-4-yl, mo holin-4-yl, 5-thioxo-4,5-dihydro-l,2,4- oxadiazol-3-yl, 5-oxo-4,5-dihydro-l,2,4-oxadiazol-3-yl, 5-
- G 4b is C 6 -Ci 0 aryl (e.g., phenyl), 5- to 10-membered heterocyclyl (e.g., dihydrobenzofuranyl), or 5- to 10-membered heteroaryl (e.g., indolyl, pyrrolyl, benzo[d]imidazolyl, pyridinyl), wherein G 4b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, hydroxy, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, -S(0)-Ci- Cgalkyl, -S(0) 2 -Ci-C 6 alkyl, -C(0)-C C 6 alkyl, Ci-C 3 alkylene-OH, Ci-C 3 alkylene-0-Ci-C 3 alkyl, C C 3
- R 5 is hydrogen, C 3 -C 6 cycloalkyl (e.g., cyclopropyl), -0-Ci-C 3 alkyl (e.g., isopropoxy); and
- R 6 is hydrogen
- R is hydrogen, Ci-Ci 0 alkyl, Ci-Cioalkyl substituted with 2 hydroxy substituents, C 2 - , -L 4A -R 4c , -L 4A -G 4a , -L 4A -S(0) 2 -G 4a , -L 4A -C(0)-G 4a ,
- G a is C 3 -C 6 cycloalkyl, phenyl, 4- to 8-membered heterocyclyl, or 5- to 6-membered heteroaryl, wherein G 4a is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, Ci-C 3 haloalkyl, -OH, -0-Ci-C 3 alkyl, -O-Ci- C 3 haloalkyl, thioxo, -NH 2 , -NH(C C 3 alkyl), and -N(C C 3 alkyl) 2 ; and
- G 4b is phenyl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl wherein G 4b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, and -0-Ci-C 6 haloalkyl.
- Embodiments may include compounds of Formula (I), wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is C and V 3 is O (i.e. benzofuranyl), or wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is N, and V 3 is N (i.e. pyrazolo[l,5-a]pyridinyl), wherein:
- R 1 is (i), (ii), or (iii);
- R la at each occurrence, is each independently hydrogen or methyl
- R lb at each occurrence, is each independently hydrogen or methyl
- R 2 is R 2 -IV
- R 2a is hydrogen
- G 2b is C 6 -Ci 0 aryl (e.g., phenyl, naphthyl) or 5- to 10-membered heteroaryl (e.g., thienyl, pyridinyl), wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-Cghaloalkyl, C 2 -Ci 0 haloalkenyl, C 2 - Ciohaloalkynyl, halogen, oxo, cyano, hydroxy, -0-Ci-C 6 alkyl, and -0-Ci-C 3 haloalkyl;
- R 3 is hydrogen
- R 4 is -N(R 40 )(SO 2 R 4a );
- R 4a is methyl
- R 40 is hydrogen, d-C 6 alkyl (e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl), Ci-C 6 haloalkyl (e.g., 3-fluoropropyl, 3,3,3-trifluoropropyl, 4-fluorobutyl, 4,4,4- trifluorobutyl), -L 4A -R 4c , -L -G , or
- L 4A is d-doalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , 5-methylhexyl, -(CH 2 ) 3 CH(CH 3 )-);
- R 4c is -0-R 4b , cyano, -C(0)N(R 4b ) 2 , -S(0)R 4b , -S(0) 2 R 4b , -S0 2 N(R 4b ) 2 , or -C(0)R 4b ;
- R 4b is each independently hydrogen or Ci-C 3 alkyl (e.g., methyl, ethyl);
- G 4a is C 3 -C 6 cycloalkyl, phenyl, 4- to 8-membered heterocyclyl, or 5- to 6-membered heteroaryl, wherein G 4a is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, Ci-C 3 haloalkyl, -OH, -0-Ci-C 3 alkyl, -O-Ci- C 3 haloalkyl, thioxo, -NH 2 , -NH(C C 3 alkyl), and -N(C C 3 alkyl) 2 ;
- G 4b is phenyl, 5- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl wherein G 4b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, and -0-Ci-C 6 haloalkyl;
- R 5 is hydrogen, cyclopropyl, or isopropoxy
- R 6 is hydrogen
- R 5 is cyclopropyl
- Embodiments may include compounds of Formula (I), wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is N, and V 3 is N (i.e. pyrazolo[l,5-a]pyridinyl), wherein:
- R is (i);
- R 40 is Ci-C 6 alkyl; and R is hydrogen or halogen.
- Embodiments may include compounds of Formula (I), wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is C and V 3 is O (i.e. benzofuranyl), or wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is N, and V 3 is N (i.e. pyrazolo[l,5-a]pyridinyl), are particular groups of compounds wherein:
- R 40 is -L 4A -G 4a -G 4b ;
- Ci-C 3 alkylene is Ci-C 3 alkylene; and wherein G is C 6 -Ci 0 aryl (e.g., phenyl, 4-(methylsulfinyl)phenyl,
- Embodiments may include compounds of Formula (I), wherein:
- R 1 is (i), (ii), (iii), (iv), or (v);
- R la is hydrogen, halogen, Ci-C 3 alkyl, or Ci-C 3 haloalkyl
- R lb is each independently hydrogen, halogen, Ci-C 3 alkyl, or Ci- C 3 haloalkyl, wherein two geminal R lb taken together optionally are oxo;
- R lc is Ci-C 3 alkyl
- R 2 is G 2a ;
- G 2a is C 6 -Ci 0 aryl optionally substituted with a substituent selected from the group consisting of R 20 or G J 2b ;
- R 20 is hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl, C 2
- Ciohaloalkenyl, C 2 -Ci 0 haloalkynyl, halogen, -N(R 2a )(R 2b ), -0-R 2b , or -C( CH 2 )R 2b ;
- R 2a is hydrogen or Ci-C 3 alkyl
- L 2C is Ci-C 6 alkylene;
- R c is C0 2 (Ci-C 3 alkyl) or -OC(0)Ci-C 3 alkyl;
- G 2b is C 3 -Ciocycloalkyl, C 5 -Ciocycloalkenyl, C 6 -Ci 0 aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, Ci-Ciohaloalkyl, C 2 - Ciohaloalkenyl, C 2 -Ci 0 haloalkynyl, halogen, oxo, cyano, hydroxy, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, -Ci-C 3 alkylene-0-H, -Ci-C 3 alkylene-0-C C 6 alkyl, C(0)H, -C C
- R 3 is hydrogen
- R 4 is hydrogen, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, cyano, -NH 2 , or -N(R 40 )(SO 2 R 4a );
- R 4a is Ci-C 6 alkyl
- R 40 is hydrogen, Ci-Ci 0 alkyl, Ci-Ci 0 alkyl substituted with 2 hydroxy substituents, C 2 - C 10 alkenyl, Q-Qohaloalkyl, C 2 -C 10 haloalkenyl, -L 4A -R 4c , -L 4A -G 4a , -L 4A -S(0) 2 -G 4a , -L 4A -C(0)-G 4a , or -L 4A -0-G 4a ;
- L 4A is Ci-Ci 0 alkylene
- R 4c is -0-R 4b , -S-R 4b , -N(R 4b ) 2 , -N(R 4b )S(0) 2 R 4b , -OC(0)R 4b , -N(R 4b )C(0)R 4b , cyano, -C(0)N(R 4b ) 2 , -C(0)N(R 4b )S(0) 2 R 4b , -S(0)R 4b , -S(0) 2 R 4b , -S0 2 N(R 4b ) 2 , -C0 2 R 4b , -C(NOH)N(R 4b ) 2 , -C(0)R 4b , -C(0)C(OH)(R 4b ) 2 , or -P(0)(OR 4b ) 2 ;
- R 4b at each occurrence, is each independently hydrogen or Ci-C 6 alkyl
- G 4a is C 3 -Ci 2 cycloalkyl, C 6 -Ci 2 aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl wherein G 4a is optionally substituted with G 4b and optionally substituted with 1 , 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 3 alkyl, Ci-C 3 haloalkyl, -OH, -0-Ci-C 3 alkyl, -0-C C 3 haloalkyl, thioxo, -NH 2 , -NH(C C 3 alkyl), and -N(C C 3 alkyl) 2 ;
- G 4b is C 3 -Ci 2 cycloalkyl, 3- to 12-membered heterocyclyl, C 6 -Ci 2 aryl, or 5- to 12-membered heteroaryl, wherein G 4b is optionally substituted with 1 , 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, hydroxy, -0-Ci-C 6 alkyl, -O-Ci- Cghaloalkyl, -S(0)-Ci-C 6 alkyl, -S(0) 2 -Ci-C 6 alkyl, -C(0)-C C 6 alkyl, Ci-C 3 alkylene-OH, C r
- Ci-C 3 alkylene-N(C C 3 alkyl) 2 Ci-C 3 alkylene-(N-heterocyclyl);
- R 5 is G 5a .
- G 5a is phenyl, wherein G 5a is substituted with -C(0)N(R 5a )-L 5B -G 5b , -C(0)-G 5f , or
- G 5b is C 3 -Ci 2 cycloalkyl, C 6 -Ci 2 aryl, 3- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, wherein each G 5b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -O-R 5 , -CN, -L 5L -0-R 5 , -L 5L -CN, and G 5c ;
- G 5c at each occurrence, is each independently C 3 -Cscycloalkyl, C6-Cioaryl, 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloal
- G 5d is each independently C 3 -C 8 cycloalkyl, C 6 -Ci 0 aryl, 4-to 10- membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5d is optionally substituted with
- substituents selected from the group consisting of oxo, halogen, Ci-C 6 alkyl, d- Cghaloalkyl, -0-R 5D , -CN, -N(R 5d )C(0)R 5D , -CON(R 5A )(R 5D ), -C(0)R 5D , -OC(0)R 5D , -C0 2 H, -C0 2 R 5D , -N(R 5d )C(0)N(R 5D ) 2 , -S-R 5D , -S(0) 2 R 5D , -S(0)R 5D , -S0 2 N(R 5A )(R 5D ), -N(R 5A )(R 5D ), -N(R 5D )S(0) 2 R 5D , N(R 5d )C(0)0(R 5D ), -L 5C -0-R 5D , -L 5C
- R 5A is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or C 3 - Cscycloalkyl, wherein the C 3 -C 8 cycloalkyl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Q- alkyl, and Ci-C 3 haloalkyl;
- R 5B is each independently hydrogen, Ci-Cioalkyl, C 2 -Cioalkenyl, C 2 - Cioalkynyl, Ci-Ciohaloalkyl, -L 5D -G 5e , or -L 5G -R 5C ;
- R 5C is each independently -CON(R 5A )(R 5G ), -0-R 5G , -OC(0)R 5G , -CN, -C(0)R 3 ⁇ 4 , -C0 2 H, -C0 2 R 5E , -N(R 5E )C(0)N(R 5E ) 2 , -S-R 5E , -S(0) 2 R 5E , -S(0)R 5E , -S0 2 N(R 5A )(R 5G ), -N(R 5A )(R 5G ), -N(R 5g )C(0)R 5G , or -N(R 5g )S(0) 2 R 5G ;
- R 5D is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or -L 5F -
- R 5E is hydrogen, Ci-Ci 0 alkyl, C 2 -Ci 0 alkenyl, C 2 -Ci 0 alkynyl, C Ci 0 haloalkyl, or -L 5E -R 5F ;
- R 5F is -CON(R 5A )(R 5D ), -0-R 5D , -CN, -C(0)R 5D , -C0 2 H, -C0 2 R 5D , -N(R 5d )C(0)N(R 5D ) 2 , -S(0) 2 R 5D , -S(0)R 5D , -S0 2 N(R 5A )(R 5D ), -N(R 5A )(R 5D ), -N(R 5d )C(0)R 5D , or -N(R 5d )S(0) 2 R 5D ;
- R 5G is each independently hydrogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, or -L 5H -
- G 5e is each independently C 3 -C 8 cycloalkyl, C 6 -Ci 0 aryl, 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl, wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -OH, -0-Ci-C 6 alkyl, and -0-C C 6 haloalkyl;
- G 5f is 4- to 10-membered heterocyclyl, wherein G 5f is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen, oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -O-Ci- C 6 alkyl, and -0-Ci-C 6 haloalkyl;
- L 5B is a bond, Ci-C 6 alkylene, or C 3 -C 8 cycloalkyl, wherein L 5B is optionally substituted with 1,
- L 5C is each independently Ci-Cealkylene or C 3 -Cscycloalkyl, wherein L 5C is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L is each independently bond, Ci-C 6 alkylene, or C 3 -C 8 Cycloalkyl, wherein L 5D is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5E is each independently Ci-C 6 alkylene, wherein L 5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently bond or Ci-C 6 alkylene, wherein L 5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5G is each independently Ci-C 6 alkylene, wherein L 5G is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5H is each independently bond or Ci-C 6 alkylene, wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- R 6 is hydrogen or fluorine
- R 7 is hydrogen
- Such embodiments may include compounds where R 2 is R 2 -II or R 2 -IV, and G 2b and R 20 are as defined herein.
- Such embodiments may include compounds where R 5 is R 5 -I or R 5 -III, and G 5b , R 5a , R 5e , and as defined hereinabove, and G 5a is further optionally substituted as described herein.
- Such embodiments may include compounds where R 2 is R 2 -II or R 2 -IV; R 5 is R 5 -I or R 5 -III; G 2b , R 20 , G 5b , R 5a , R 5e , and L 5B are as defined herein; and G 5a is further optionally substituted as described herein.
- R 1 is (i), (ii), (iii), (iv), or (v);
- R la is hydrogen, halogen, Ci-C 3 alkyl, or Ci-C 3 haloalkyl
- R lb is each independently hydrogen, halogen, Ci-C 3 alkyl, or Ci- C 3 haloalkyl, wherein two geminal R lb taken together optionally are oxo;
- R lc is Ci-C 3 alkyl
- R 2 is R 2 -II or R 2 -IV;
- R 5 is R 5 -I or R 5 -III;
- R 2a is hydrogen or Ci-C 3 alkyl (e.g. methyl);
- G 2b is C 3 -Ciocycloalkyl (e.g., cyclopropyl, cyclobutyl), C 5 -Ci 0 cycloalkenyl (e.g., cyclohexenyl), C 6 -Ci 0 aryl (e.g., phenyl), 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridyl, thiophenyl, indolyl, benzo[d]oxadiazolyl), wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-C 6 alkyl (e.g., methyl, ethyl, t-butyl, hexyl), C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl (e.g., trifluoromethyl,
- L 2C is Q-Qalkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 , -(CH 2 ) 3 -);
- R 2c is C0 2 (Ci-C 3 alkyl) or -OC(0)Ci-C 3 alkyl;
- R 3 is hydrogen
- R 4 is hydrogen, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, cyano, -NH 2 , or -N(R 40 )(SO 2 R 4a );
- R 4a is Ci-C 3 alkyl (e.g., methyl);
- R 40 is hydrogen, Ci-C 6 alkyl (e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl), Ci-C 6 haloalkyl (e.g., 3-fluoropropyl, 3,3,3-trifluoropropyl, 4-fluorobutyl, 4,4,4- trifluorobutyl), C 2 -C 6 haloalkenyl (e.g., 5,6,6-trifluorohex-5-enyl), or -L 4A -R 4c ;
- Ci-C 6 alkyl e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl
- Ci-C 6 haloalkyl e.g., 3-fluoropropyl,
- L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , 5-methylhexyl);
- R 4c is -0-R 4b ;
- R 4b is hydrogen or Ci-C 6 alkyl (e.g., methyl, ethyl);
- R 6 is hydrogen or fluorine
- R 7 is hydrogen
- G 5b , R 5a , R 5e , and L 5B are as defined herein; and G 5a is further optionally substituted as described herein.
- Embodiments may include compounds of formula (I), wherein W 1 is CR 6 , W 2 is CR 5 , W 3 is CR 4 , W 4 is CR 3 , V 1 is C, V 2 is C and V 3 is O (i.e. benzofuranyl), wherein R 1 is (i), (ii), (iii), or (v).
- Embodiments may include compounds of formula (I) wherein R 1 is (i), (ii), (iii), or (v). Such embodiments may include compounds wherein:
- R la is each independently hydrogen, halogen (e.g., fluoro), Ci-C 3 alkyl (e.g., ), or Ci-C 3 haloalkyl (e.g., trifluoromethyl);
- R lb is each independently hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, propyl), wherein two geminal R lb taken together optionally are oxo;
- R 2 is R 2 -II or R 2 -IV;
- R 2a is hydrogen or Ci-C 3 alkyl (e.g. methyl);
- R 2b is Ci-Cioalkyl (e.g., isopentyl, isopropyl) or L 2C -R 2c ;
- G 2b is C 3 -Ciocycloalkyl (e.g., cyclopropyl, cyclobutyl), C 5 -Ci 0 cycloalkenyl (e.g., cyclohexenyl), C 6 -Ci 0 aryl (e.g., phenyl), 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridyl, thiophenyl, indolyl, benzo[d]oxadiazolyl), wherein G 2b is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of Ci-C 6 alkyl (e.g., methyl, ethyl, t-butyl, hexyl), C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C 6 haloalkyl (e.g., trifluoromethyl,
- L 2C is d-Cgalkylene (e.g., CH 2 , -C(CH 3 )(H)-, CH 2 CH 2 , -(CH 2 ) 3 -);
- R 2c is C0 2 (Ci-C 3 alkyl) or -OC(0)Ci-C 3 alkyl;
- R 3 is hydrogen
- R 4 is hydrogen, halogen, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl, -0-Ci-C 6 haloalkyl, cyano, -NH 2 , or -N(R 40 )(SO 2 R 4a );
- R 4a is Ci-C 3 alkyl (e.g., methyl);
- R 40 is hydrogen, d-C 6 alkyl (e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl), Ci-C 6 haloalkyl (e.g., 3-fluoropropyl, 3,3,3-trifluoropropyl, 4-fluorobutyl, 4,4,4- trifluorobutyl), C 2 -C 6 haloalkenyl (e.g., 5,6,6-trifluorohex-5-enyl), or -L 4A -R 4c ;
- d-C 6 alkyl e.g., ethyl, propyl, isobutyl, isopentyl, n-pentyl, n-hexyl, 4- methylpentyl
- Ci-C 6 haloalkyl e.g., 3-fluoropropy
- L 4A is Ci-Cioalkylene (e.g., CH 2 , CH 2 CH 2 , (CH 2 ) 3 , (CH 2 ) 4 , 5-methylhexyl);
- R 4c is -0-R 4b ;
- R 4b is hydrogen or Ci-C 6 alkyl (e.g., methyl, ethyl);
- R 5 is R 5 -II
- L 5B is d-Cgalkylene (e.g., -CH 2 -, -C(CH 3 ) 2 - -C(CH 3 )(H)CH 2 -, -C(CH 3 ) 2 CH 2 -) or C 3 - Cscycloalkyl (e.g., cyclopropyl, cyclobutyl);
- G 5 is CrCscycloaikyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl), C 6 -Ci 0 aryl (e.g., phenyl, naphthyl, indanyl), 3- to 8-membered heterocyclyl (e.g., tetrahydrofuranyl, tetrahydropyranyl), or 5- to 10-membered heteroaryl (e.g., furanyl, imidazolyl, thiazoly
- Ci-C 6 alkyl e.g., methyl, ethyl, isopropyl
- Q- C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., hydroxy, methoxy
- -CN methoxymethyl, cyanomethyl, and G 5c ;
- G 5c is each independently cyclopropyl, phenyl, or 5- to 6-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), Ci- C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -0-Ci-C 6 alkyl (e.g., methoxy), and -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- halogen e.g., fluoro, chloro
- Ci- C 6 alkyl e.g., methyl, ethyl
- Ci-C 6 haloalkyl e.g.,
- R 50 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C3haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 51 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy), or G 5d ;
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- G 5d is phenyl, tetrahydropyrimidinyl, furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, or indolyl;
- R 5b is hydrogen, Ci-C 6 alkyl (e.g., methyl), C 2 -C 6 alkenyl (e.g., allyl), C 2 -C 6 alkynyl (e.g., propargyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2-difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl, -CH 2 -pyrrolidin-3-yl, -CH 2 CH 2 -nK ⁇ holin-4-yl, -CH 2 CH 2 CH 2 -nK ⁇ holin-4-yl, -CH 2 CH 2 -mo ⁇ holin-2-yl -CH 2 CH 2 -4-methylpiperazin- 1 -yl,
- R 5c is -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g ,
- R 5g is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci- Cghaloalkyl (e.g., 2,2-difluoroethyl), or -L 5H -G 5e (e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl);
- Ci-C 6 alkyl e.g., methyl, ethyl
- Ci- Cghaloalkyl e.g., 2,2-difluoroethyl
- -L 5H -G 5e e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl
- L 5D is a bond, C C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- C C 6 alkylene e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- G 5e is each independently C 3 -C 6 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 7-membered heterocyclyl (e.g., mo ⁇ holin-4-yl, pyrrolidin-l-yl, 4- methylpiperazin-l-yl, piperidinyl), or 5- to 6-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4-yl), wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -OH, -O-Ci-
- halogen
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 )2-,-C(CH 3 )2-, - C(C3 ⁇ 4) 2 CH 2 - -CH 2 CH(CH 3 )-);
- R 5d is each independently hydrogen, Ci-C 6 alkyl, or Ci-C 6 haloalkyl;
- R 5a is hydrogen or methyl
- R 6 is hydrogen
- R 5 is R 5 -II
- G 5b is phenyl or pyridinyl (e.g. pyridin-2-yl), wherein G 5b is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of oxo, halogen (e.g. fluoro), Ci-Cealkyl (e.g., methyl, ethyl, isopropyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -0-R 5d (e.g., hydroxy, methoxy), and -CN.
- substituents selected from the group consisting of oxo, halogen (e.g. fluoro), Ci-Cealkyl (e.g., methyl, ethyl, isopropyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -0-R 5d (e.g., hydroxy, methoxy), and -CN.
- R 5 is R 5 -IV
- R a is hydrogen or methyl
- R 5e is hydrogen, Ci-Ci 0 alkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Cioalkenyl, C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ciohaloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl), or -L 5E -R 5f (e.g., -C(CH 3 ) 2 -CONHMe, -C(CH 3 ) 2 -CONHCH 2 CHF 2 , -C(CH 3 ) 2 - C0 2 CH 3 , -C(CH 3 ) 2 CH 2 -C(0)CH 3 , -C(CH 3 ) 2 -CONH-thiazol-2-yl);
- R 5f is -CON(R 5a )(R 5d ) (e.g., CONHMe, CONHCH 2 CHF 2 , CONH-thiazol-2-yl), -0-R 5d (e.g., OMe), -CN, -C(0)R 5d (e.g., C(0)CH 3 ), -C0 2 H, -C0 2 R 5d (e.g., C0 2 CH 3 ), -N(R 5d )C(0)N(R 5d ) 2 , -S(0) 2 R 5d (e.g., S(0) 2 Me), -S(0)R 5d (e.g., S(O)Me), -S0 2 N(R 5a )(R 5d ) (e.g., S0 2 NH 2 , S0 2 NHEt), -N(R 5a )(R 5d ), -N(R 5d )C(0)R 5d (e.g., NHC(O
- R 5d is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci- Cehaloalkyl (e.g., 2,2-difluoroethyl), or -L 5F -G 5c (e.g., bond-thiazol-2-yl);
- Ci-C 6 alkyl e.g., methyl, ethyl
- Ci- Cehaloalkyl e.g., 2,2-difluoroethyl
- -L 5F -G 5c e.g., bond-thiazol-2-yl
- G 5c is each independently C 3 -C 8 cycloalkyl (e.g., cyclopropyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), oxo, Q-Cealkyl, Ci-Cehaloalkyl, -0-Ci-C 6 alkyl (e.g., methoxy), and -0-Ci-C 6 haloalkyl;
- halogen e.g., fluoro, chloro
- Q-Cealkyl Ci-Cehaloalkyl
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-Ci 0 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-Ci 0 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-Ci 0 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- R 5b is hydrogen, Ci-C 6 alkyl (e.g., methyl), C 2 -C 6 alkenyl (e.g., allyl), C 2 -C 6 alkynyl (e.g., propargyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2-difluoroethyl), -L 5D -G 5e (e.g., bond-G 5e , -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl, -CH 2 -pyrrolidin-3-yl, -CH 2 CH 2 -nK ⁇ holin-4-yl, -CH 2 CH 2 CH 2 -nK ⁇ holin-4-yl, -CH 2 CH 2 -nK ⁇ holin-2-yl -CH 2 CH 2 -4-methylpiperazin- 1 -yl,
- G 5e is C 3 -C 6 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 7- membered heterocyclyl (e.g., ⁇ 1 ⁇ 1 ⁇ -4 ⁇ 1, pyrrolidin-l-yl, 4-methylpiperazin-l -yl, piperidinyl), or 5- to 6-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4-yl), wherein G 5e is optionally substituted with 1 or 2 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C 6 alkyl (e.g.,
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5g is hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci-C 6 haloalkyl (e.g., 2,2-difluoroethyl), or -L 5H -G 5e (e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl);
- L 5D is a bond, C C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- C C 6 alkylene e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- L 5E is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -), wherein L 5E is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently a bond or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5F is optionally substituted with 1 , 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 -, -CH 2 CH(CH 3 )-); and
- L 5H is each independently a bond, or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5H is each optionally substituted with 1 , 2, 3, or 4 halogen and 1 or 2 hydroxy.
- Such embodiments may include compounds wherein:
- R 5 is R 5 -IV
- R 5a is hydrogen or methyl
- R 5e is hydrogen, Ci-Cioalkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Ci 0 alkenyl, or C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ci 0 haloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl);
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy);
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), -0-Ci-C 6 haloalkyl (e.g., trifluoromethoxy), or G 5d ;
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C 6 haloalkyl e.g., trifluoromethoxy
- G 5d is C 3 -C 8 cycloalkyl, C 6 -Cioaryl (e.g., phenyl), 4-to 10-membered heterocyclyl (e.g., tetrahydropyrimidinyl), or 5- to 10-membered heteroaryl (e.g., furanyl, thienyl, pyrazolyl, pyridinyl, pyrimidinyl, oxadiazolyl, isoquinolinyl, indolyl), wherein G 5d is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of oxo, halogen (e.g.
- Ci-C 6 alkyl e.g., methyl, ethyl, n-propyl, isopropyl
- Ci-C 6 haloalkyl e.g., trifluoromethyl
- -0-R 5d e.g., methoxy, ethoxy
- -CN e.g., -N(R 5a )C(0)R 5d (e.g., NHC(O)Me)
- -CON(R 5a )(R 5d ) e.g., CONH 2 ,
- N(R 5a )C(0)0(R 5d ) e.g., NHC(O)OMe
- -L 5C -0-R 5d e.g., hydroxymethyl, methoxymethyl
- -L 5C -CN e.g., cyanomethyl
- G 5c e.g., phenyl
- -L 5C -G 5c e.g., benzyl
- R 5d is each independently hydrogen, Ci-C 6 alkyl (e.g., methyl, ethyl), Ci- Cehaloalkyl (e.g., 2,2-difluoroethyl), or -L 5F -G 5c (e.g., bond-thiazol-2-yl);
- Ci-C 6 alkyl e.g., methyl, ethyl
- Ci- Cehaloalkyl e.g., 2,2-difluoroethyl
- -L 5F -G 5c e.g., bond-thiazol-2-yl
- L 5C is each independently Ci-C 6 alkylene or C 3 -C 8 cycloalkyl, wherein L 5C is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy;
- L 5F is each independently a bond or Ci-C 6 alkylene (e.g., -CH 2 -), wherein L 5F is optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy; and
- G 5c is each independently C 3 -C 8 cycloalkyl (e.g., cyclopropyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl (e.g., pyridinyl, thiazolyl, isoxazolyl, pyrazolyl), wherein G 5c is optionally substituted with 1, 2, 3, 4, or 5 substituents selected from the group consisting of halogen (e.g., fluoro, chloro), oxo, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -0-Ci-C 6 alkyl (e.g., methoxy), and -0-Ci-C 6 haloalkyl.
- halogen e.g., fluoro, chloro
- oxo Ci-C 6 alkyl
- Ci-C 6 haloalkyl e
- R 5a is hydrogen or methyl
- R e is hydrogen, Ci-Cioalkyl (e.g., methyl, ethyl, isopropyl, n-butyl, isobutyl, t-butyl), C 2 - Ci 0 alkenyl, or C 2 -Ci 0 alkynyl (e.g., 2-methylbut-3-yn-2-yl), Ci-Ci 0 haloalkyl (e.g., l,l,l-trifluoro-2- methylpropan-2-yl);
- R 52 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), or -0-R 5b ;
- R 53 is hydrogen, Ci-C 3 alkyl (e.g., methyl, ethyl, isopropyl), Ci-C 3 haloalkyl (e.g., trifluoromethyl), halogen (e.g., fluoro, chloro), -0-Ci-C 6 alkyl (e.g., methoxy), or -0-Ci-C ⁇ shaloalkyl (e.g., trifluoromethoxy);
- Ci-C 3 alkyl e.g., methyl, ethyl, isopropyl
- Ci-C 3 haloalkyl e.g., trifluoromethyl
- halogen e.g., fluoro, chloro
- -0-Ci-C 6 alkyl e.g., methoxy
- -0-Ci-C ⁇ shaloalkyl e.g., trifluoromethoxy
- R 5b is hydrogen, d-C 6 alkyl (e.g., methyl), Ci-C 6 haloalkyl (e.g., trifluoromethyl, 2,2- difluoroethyl), -L 5D -G 5e (e.g., bond-cyclopropyl, bond-cyclobutyl, -CH 2 CH 2 -pyrrolidin-l-yl, -CH 2 -pyrrolidin-2-yl, -CH 2 -pyrrolidin-3-yl, -CH 2 CH 2 -morpholin-4-yl, -CH 2 CH 2 CH 2 -mo holin-4-yl, -CH 2 CH 2 -mo holin-2-yl -CH 2 CH 2 -4-methylpiperazin-l-yl, -CH 2 CH 2 -piperidinyl, -CH 2 -piperidin-3- yl, -CH 2 -pyridin-2-yl, -CH 2
- G 5e is C 3 -C 6 cycloalkyl (e.g., cyclobutyl, cyclopentyl), C 6 -Ci 0 aryl (e.g., phenyl), 4-to 7- membered heterocyclyl (e.g., morpholin-4-yl, pyrrolidin-l-yl, 4-methylpiperazin-l-yl, piperidinyl), or 5- to 6-membered heteroaryl (e.g., pyridin-2-yl, imidazol-4-yl), wherein G 5e is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of halogen (e.g., fluoro), oxo, C ⁇ - Cgalkyl (e.g., methyl, ethyl), C C 6 haloalkyl (e.g., trifluoromethyl), -OH, -0-Ci-C 6 alkyl (e.g., O
- R 5c is each independently -CON(R 5a )(R 5g ) (e.g., CONH 2 ), -0-R 5g (e.g., OH, OMe), -OC(0)R 5g , -CN, -C(0)R 5g , -C0 2 H, -C0 2 R 5g , -N(R 5g )C(0)N(R 5g ) 2 (e.g., NHC(0)NH 2 ), -S-R 5g , -S(0) 2 R 5g , -S(0)R 5g , -S0 2 N(R 5a )(R 5g ), -N(R 5a )(R 5g ) (e.g., NH 2 , N(CH 3 ) 2 ), -N(R 5g )C(0)R 5g , or -N(R 5g )S(0) 2 R 5g ;
- R 5g is hydrogen, d-C 6 alkyl (e.g., methyl, ethyl), d-C 6 haloalkyl (e.g., 2,2-difluoroethyl), or -L 5H -G 5e (e.g., bond-C 3 -C 6 cycloalkyl, -CH 2 -C 3 -C 6 cycloalkyl);
- L 5D is a bond, C C 6 alkylene (e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -), or C 3 -C 6 cycloalkyl (e.g., cyclopropyl);
- C C 6 alkylene e.g., -CH 2 - -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -
- C 3 -C 6 cycloalkyl e.g., cyclopropyl
- L 5G at each occurrence is each independently Ci-C 6 alkylene (e.g. -(CH 2 ) 2 -,-C(CH 3 ) 2 -, - C(CH 3 ) 2 CH 2 - -CH 2 CH(CH 3 )-); and
- L 5H is each independently bond, or Ci-Cealkylene (e.g., -CH 2 -), wherein L 5H is each optionally substituted with 1, 2, 3, or 4 halogen and 1 or 2 hydroxy.
- Exemplary compounds include, but are not limited to:
- Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
- Individual stereoisomers of compounds of the present application may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution which is well known to those of ordinary skill in the art.
- Geometric isomers may exist in the disclosed compounds.
- the present disclosure contemplates the various geometric isomers and mixtures thereof resulting from the disposition of substituents around a carbon-carbon double bond, a carbon-nitrogen double bond, a cycloalkyl group, or a heterocycle group.
- Substituents around a carbon-carbon double bond or a carbon-nitrogen bond are designated as being of Z or E configuration and substituents around a cycloalkyl or a heterocycle are designated as being of cis or trans configuration.
- the disclosure also include isotopically-labeled compounds, which are identical to disclosed compounds, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the disclosed compounds are hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as, but not limited to, 2 H, H, 1 C, 14 C, 15 N, ls O, 17 0, 1 P, 2 P, 5S, 18 F, and 6 C1, respectively.
- positron-emitting isotopes are useful in medical imaging and positron- emitting tomography (PET) studies for determining the distribution of receptors.
- Suitable positron- emitting isotopes that can be incorporated in compounds of formula (I) are n C, 1 N, 15 0, and 18 F.
- Isotopically-labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using appropriate isotopically-labeled reagent in place of non-isotopically- labeled reagent. Salts
- a salt of a compound may be advantageous due to one or more of the salt's properties, such as, for example, enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or other solvents.
- the salt may be pharmaceutically acceptable and/or physiologically compatible.
- pharmaceutically acceptable is used adjectivally in this disclosure to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product.
- salts include, for example, salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
- these salts typically may be prepared by conventional means by reacting, for example, the appropriate acid or base with a disclosed compound.
- Pharmaceutically acceptable acid addition salts of the disclosed compounds can be prepared from an inorganic or organic acid.
- suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid.
- Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
- suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2- hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenic acid, beta-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, butyrate, camphorate, camphorsulfonate, cyclopent
- Pharmaceutically acceptable base addition salts of the disclosed compounds include, for example, metallic salts and organic salts.
- Metallic salts may include alkali metal (group la) salts, alkaline earth metal (group Ila) salts, and other physiologically acceptable metal salts.
- Such salts may be made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.
- Organic salts can be made from amines, such as tromethamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine.
- Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl (Ci- C 6 ) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
- Lower alkyl (Ci- C 6 ) halides e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides
- dialkyl sulfates e.g., dimethyl
- the disclosed compounds (and salts thereof) with any level of purity are within the scope of the present disclosure.
- substantially pure in reference to a compound/salt/isomer, means that the preparation/composition containing the compound/salt/isomer contains more than about 85% by weight of the compound/salt/isomer, more than about 90% by weight of the compound/salt/isomer, more than about 95 % by weight of the compound/salt/isomer, more than about 97%o by weight of the compound/salt/isomer, and more than about 99%> by weight of the compound/salt/isomer.
- compositions comprising one or more of the disclosed compounds and/or salts thereof.
- the compositions comprise one or more substantially phase pure crystalline forms.
- the compositions may be pharmaceutical compositions.
- compositions further comprise one or more additional therapeutic agents.
- therapeutic agents may include one or more therapeutic agents used to treat hepatitis C ⁇ e.g., interferon or interferon/ribavirin combination, or an HCV inhibitor such as, for example, an HCV polymerase inhibitor or an HCV protease inhibitor).
- HCV inhibitor such as, for example, an HCV polymerase inhibitor or an HCV protease inhibitor.
- the disclosed compound(s) and/or salt(s) thereof can also be co-administered with therapeutic agents other than therapeutic agents used to treat hepatitis C (e.g., anti-HIV agents such as ritonavir).
- composition may depend on the method of administration, and may comprise one or more conventional pharmaceutically acceptable carriers, adjuvants, and/or vehicles (together referred to as "excipients").
- excipients formulation of drugs is generally discussed in, for example, Hoover, J.,
- Solid dosage forms for oral administration include, for example, capsules, tablets, pills, powders, and granules.
- the disclosed compounds or salts are ordinarily combined with one or more excipients.
- the compounds or salts can be mixed with, for example, lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
- Such capsules or tablets can contain a controlled-release formulation, as can be provided in, for example, a dispersion of the compound or salt in hydroxypropylmethyl cellulose.
- the dosage forms also can comprise buffering agents, such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills additionally can be prepared with enteric coatings.
- Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions (including both oil-in-water and water-in-oil emulsions), solutions (including both aqueous and non-aqueous solutions), suspensions (including both aqueous and non-aqueous suspensions), syrups, and elixirs containing inert diluents commonly used in the art (e.g., water).
- Such compositions may also comprise, for example, wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
- Parenteral administration includes subcutaneous injections, intravenous injections, intramuscular injections, intrasternal injections, and infusion.
- Injectable preparations e.g., sterile injectable aqueous or oleaginous suspensions
- suitable dispersing, wetting agents, and/or suspending agents include, for example, water, 1 ,3-butanediol, Ringer's solution, isotonic sodium chloride solution, bland fixed oils (e.g., synthetic mono- or diglycerides), fatty acids (e.g., oleic acid), dimethyl acetamide, surfactants (e.g. , ionic and non-ionic detergents), and/or polyethylene glycols.
- Formulations for parenteral administration may, for example, be prepared from sterile powders or granules having one or more of the excipients mentioned for use in the formulations for oral administration.
- a compound or salt of the invention can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
- the pH may be adjusted, if necessary, with a suitable acid, base, or buffer.
- Suppositories for rectal administration may be prepared by, for example, mixing a compound or salt of the invention with a suitable nonirritating excipient that is solid at ordinary temperatures, but liquid at the rectal temperature, and will, therefore, melt in the rectum to release the drug.
- suitable excipients include, for example, cocoa butter; synthetic mono-, di-, or triglycerides, fatty acids, and/or polyethylene glycols.
- Topical administration includes the use of transdermal administration, such as transdermal patches or iontophoresis devices.
- the total daily dose of the compound or salt may be from about 0.001 to about lOOmg/kg, from about 0.001 to about 30mg/kg, or from about 0.01 to about lOmg/kg (i.e.,mg of the compound or salt per kg body weight).
- Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose.
- the administration of the compound or salt will be repeated a plurality of times. Multiple doses per day typically may be used to increase the total daily dose, if desired.
- Factors affecting the dosage regimen include the type, age, weight, sex, diet, and condition of the patient; the severity of the pathological condition; the severity of the pathological condition; the route of administration; pharmacological considerations, such as the activity, efficacy,
- the dosage regimen actually employed can vary widely, and therefore, can derive from the dosage regimen set forth above.
- kits comprising one or more of the disclosed compounds and/or salts thereof.
- the kits may optionally contain one or more additional therapeutic agents and/or instructions for, for example, using the kit.
- This disclosure is also directed, in part, to methods for inhibiting replication of a ribonucleic acid (RNA) virus.
- the method comprises exposing the virus to one or more of the disclosed compounds and/or salts thereof.
- replication of the RNA virus is inhibited in vitro.
- replication of the RNA virus is inhibited in vivo.
- the RNA virus whose replication is being inhibited is a single-stranded, positive sense RNA virus.
- the RNA vims whose replication is being inhibited is a virus from the Flaviviridae family.
- the RNA virus whose replication is being inhibited is HCV.
- the RNA virus whose replication is being inhibited is any one of HCV genotypes la, lb, 2a, 3a and 4a. In embodiments, the RNA virus whose replication is being inhibited is a mutant form of HCV. In embodiments, the RNA virus whose replication is being inhibited is a mutant form of HCV genotype la or lb. In embodiments, the mutation occurring in HCV genotype la or lb is a C316Y mutation.
- This disclosure is also directed, in part, to methods for inhibiting HCV RNA polymerase.
- the method comprises exposing the polymerase with one or more of the disclosed compounds and/or salts thereof.
- HCV RNA polymerase activity is inhibited in vitro.
- HCV RNA polymerase activity is inhibited in vivo.
- the HCV RNA polymerase whose replication is being inhibited is a mutant form of HCV RNA polymerase genotype la or 1 b.
- the mutation occurring in HCV RNA polymerase genotype la or lb is a C316Y mutation.
- RNA virus replication/HCV polymerase activity means reducing the level of RNA virus replication/HCV polymerase activity either in vitro or in vivo. For example, if a disclosed compound/salt reduces the level of RNA virus replication by at least about 10% compared to the level of R A virus replication before the virus was exposed to the compound/salt, then the compound/salt inhibits RNA virus replication. In some embodiments, the compound/salt can inhibit RNA virus replication by at least about 20%, at least about 30%, at least about 40%o, at least about 50%>, at least about 60%>, at least about 70%o, at least about 80%>, at least about 90%>, or at least about 95%.
- This disclosure is also directed, in part, to methods for treating a disease that can be treated by inhibiting HCV RNA polymerase.
- this disclosure is also directed, in part, to methods for treating hepatitis C in an animal in need of such treatment. These methods comprise administering to the animal one or more of the disclosed compounds and/or salts thereof, and, optionally, one or more additional therapeutic agents. In some embodiments, a therapeutically effective amount of the compound(s) and/or salt(s) is administered to the animal.
- “Treating” means ameliorating, suppressing, eradicating, preventing, reducing the risk of, and/or delaying the onset of the disease being treated.
- treating encompass administration of the disclosed compounds and/or salts thereof to an HCV-negative patient that is a candidate for an organ transplant.
- the methods of treatment are particularly suitable for use with humans, but may be used with other animals, particularly mammals.
- a “therapeutically-effective amount” or “effective amount” is an amount that will achieve the goal of treating the targeted condition.
- the methods comprise combination therapy, wherein the disclosed compound(s) and/or salt(s) is/are co-administered with a second (or even a third, fourth, etc.) compound, such as, for example, another antiviral therapeutic agent such as, for example, an antiviral therapeutic agent used to treat hepatitis C (e.g., interferon or interferon/ribavirin combination, or an HCV inhibitor such as, for example, an HCV polymerase inhibitor or an HCV protease inhibitor).
- a second (or even a third, fourth, etc.) compound such as, for example, another antiviral therapeutic agent such as, for example, an antiviral therapeutic agent used to treat hepatitis C (e.g., interferon or interferon/ribavirin combination, or an HCV inhibitor such as, for example, an HCV polymerase inhibitor or an HCV protease inhibitor).
- the disclosed compound(s) and/or salt(s) thereof can also be co-administered with therapeutic agents other than therapeutic agents used to treat hepatitis C (e.g., pharmacokinetic boosting agents such as ritonavir).
- therapeutic agents other than therapeutic agents used to treat hepatitis C e.g., pharmacokinetic boosting agents such as ritonavir.
- the disclosed compound(s) and/or salt(s) thereof and the second, etc. therapeutic agent(s) may be administered in a substantially simultaneous manner (e.g., or within about 5 minutes of each other), in a sequential manner, or both. It is contemplated that such combination therapies may include administering one therapeutic agent multiple times between the administrations of the other.
- the time period between the administration of each agent may range from a few seconds (or less) to several hours or days, and will depend on, for example, the properties of each composition and active ingredient (e.g., potency, solubility, bioavailability, half-life, and kinetic profile), as well as the condition of the patient.
- the disclosed compound(s) and/or salt(s) and the second, etc. therapeutic agent may also be administered in a single formulation.
- This disclosure is also directed, in part, to uses of one or more of the disclosed compounds and/or salts thereof, and, optionally one or more additional therapeutic agents to prepare a medicament.
- the medicament is for co-administration with one or more additional therapeutic agents.
- the medicament is for inhibiting replication of an RNA virus.
- the medicament is for treating hepatitis C.
- This disclosure is also directed, in part, to one or more of the disclosed compounds and/or salts thereof, and, optionally one or more additional therapeutic agents, for use as a medicament.
- the medicament is for inhibiting replication of an RNA virus.
- the medicament is for treating hepatitis C.
- ATP for adenosine triphosphate
- cpms for counts per minute
- CTP for cytidine triphosphate
- DMEM for Dulbecco's modified Eagle's medium
- DMSO for dimethyl sulfoxide
- DNA for deoxyribonucleic acid
- EDTA for ethylenediaminetetraacetic acid
- FBS for fetal bovine serum
- GTP for guanosine 5 '-triphosphate
- IRES for internal ribosome entry site
- kb for kilobase
- PCR for polymerase chain reaction
- RNA for ribonucleic acid
- RT for reverse transciptase
- RT-PCR for reverse transcriptase-polymerase chain reaction
- Tris for adenosine triphosphate
- Tris-HCl for tris(hydroxymethyl)aminomethane hydrochloride and v/v for volume/volume.
- Biochemical enzyme inhibition assays Purified HCV NS5B polymerase enzymes were used for polymerase inhibition assays. All recombinant HCV polymerases contained the first 570 amino acids of the 591 amino acid native protein sequence and a six-histidine tag at the N-terminus or C-terminus to facilitate purification by affinity chromatography.
- the DNA nucleotide sequence for the HCV polymerase lb BK strain was codon optimized for expression in E. coli.
- a synthetic gene was prepared from a series of overlapping oligonucleotides that were filled in using a DNA polymerase and amplified by PCR.
- the patient isolate HCV polymerases were cloned by RT-PCR methods using HCV RNA extracted from the serum of infected subjects obtained from ProMedDx and BioCollections (genotypes 2a, 2b, 3a, and 4a). Laboratory strains were cloned from plasmid DNA (la-H77 or la-H77-C316Y) or from existing replicon cells (lb Rice). In all cases the amplified DNA was cloned into a protein expression vector (typically a pET vector from Novagen) and then multiple clones were sequenced to identify one whose NS5B sequence agreed with the population sequence. This sequence-confirmed clone was then transfected into E.
- a protein expression vector typically a pET vector from Novagen
- E. coli for protein expression and purification.
- E. coli cultures were grown to a maximum optical density (OD) of 2-3 and then induced with 0.4 mM isopropyl beta-D-thiogalactopyranoside (IPTG) and grown for 20 hours at 20 °C.
- OD optical density
- IPTG isopropyl beta-D-thiogalactopyranoside
- Proteins were purified using nickel affinity chromatography, and additional column steps were added including, ion exchange, size exclusion, hydrophobic ion, and poly-U affinity chromatography, as needed, depending on the sample being purified.
- the template RNA used in the polymerase enzymatic assay was a 2.1 kb construct that corresponds to the 3 '-end of an HCV genotype lb negative strand RNA.
- dilutions of the inhibitors were incubated with 20 mM Tris-HCl, pH 7.4, 2 mM MnCl 2 , 80 mM potassium glutamate, 1 mM dithiothreitol (DTT), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.1 mg/mL bovine serum albumin (BSA), 60-125 ⁇ of GTP and 10-50 nM of polymerase for approximately 15 minutes.
- DTT dithiothreitol
- EDTA ethylenediaminetetraacetic acid
- BSA bovine serum albumin
- the reaction was initiated by the addition of 20 ⁇ CTP, 20 ⁇ ATP, 0.284 ⁇ (0.5 ⁇ &) of 5,6-[ H] UTP, 5 nM template RNA and 0.1 ⁇ / ⁇ RNase inhibitor (RNasin, Promega), and allowed to proceed for three hours at 30°C.
- the final reaction volume was 50 ⁇
- the reaction was terminated by the addition of 50 uL of 4 mM spermine in 10 mM Tris-HCl, pH 7.5, 1 mM EDTA.
- the quenched reaction was allowed to incubate for at least 15 minutes at room temperature, and then the precipitated RNA was captured by filtration through a glass fiber filter (GF/B, Millipore) in a 96 well format.
- GF/B glass fiber filter
- the filter plate was washed five times with 200 ⁇ , of 2 mM spermine, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, and two times with ethanol. After drying thoroughly in air, 30 ⁇ , of Microscint-20 scintillation cocktail (Perkin Elmer) was added to each well, and the retained cpm were determined by scintillation counting. IC 50 values were determined by nonlinear regression.
- the percent of inhibition was calculated at twelve inhibitor concentrations relative to the uninhibited control and then fit to equation 1.
- V cat [S]/2(K m + [S])*(sqrt ((IC 50 + I - ⁇ ) ⁇ 2 + (4* IC 50 *E))-( IC 50 + I - E)) equation 2
- the disclosed compounds achieve IC 50 s of less than about 200 ⁇ , and, as illustrated in Table 2, certain disclosed compounds achieve IC50S within a range of from about 0.001 to about 200 ⁇ . Certain disclosed compounds have IC50S less than 0.1 ⁇ .
- the disclosed compounds achieve IC 50 s of less than about 25 ⁇ , and, as illustrated in Table 2, certain disclosed compounds achieve IC 50 s within a range of from about 0.005 to about 25 ⁇ . Certain disclosed compounds have IC 50 s less than 0.1 ⁇ .
- the disclosed compounds achieve a fold resistance of less than about 600-fold, and, as illustrated in Table 2, certain compounds achieve a fold resistance within a range of about 1 to about 600. Certain disclosed compounds have a fold resistance of ⁇ 20.
- the disclosed compounds achieve IC 5 0S of less than 200 ⁇ , and as illustrated in Table 2, certain disclosed compounds achieve IC50S within a range of from about 0.005 to about 200 ⁇ . Certain disclosed compounds have IC 50 s less than 0.1 ⁇ . In the HCV polymerase assay with strain lb Rice, the disclosed compounds achieve IC50S of less than 0.1 ⁇ , and as illustrated in Table 2, certain disclosed compounds achieve IC 50 s within a range of from about 0.0025 to about 0.075 ⁇ . Certain compounds have IC 50 s less than about 0.070 ⁇ .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013546262A JP5918264B2 (en) | 2010-12-22 | 2011-12-16 | Hepatitis C inhibitor and use thereof |
CA2822357A CA2822357A1 (en) | 2010-12-22 | 2011-12-16 | Hepatitis c inhibitors and uses thereof |
CN201180068128.6A CN103649079B (en) | 2010-12-22 | 2011-12-16 | Hepatitis c inhibitor and application thereof |
MX2013007359A MX340085B (en) | 2010-12-22 | 2011-12-16 | Hepatitis c inhibitors and uses thereof. |
US13/995,701 US9173887B2 (en) | 2010-12-22 | 2011-12-16 | Hepatitis C inhibitors and uses thereof |
EP11808073.8A EP2655362A1 (en) | 2010-12-22 | 2011-12-16 | Hepatitis c inhibitors and uses thereof |
US14/852,984 US9453007B2 (en) | 2010-12-22 | 2015-09-14 | Hepatitis C inhibitors and uses thereof |
US15/240,753 US9567355B2 (en) | 2010-12-22 | 2016-08-18 | Hepatitis C inhibitors and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426312P | 2010-12-22 | 2010-12-22 | |
US61/426,312 | 2010-12-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/995,701 A-371-Of-International US9173887B2 (en) | 2010-12-22 | 2011-12-16 | Hepatitis C inhibitors and uses thereof |
US14/852,984 Division US9453007B2 (en) | 2010-12-22 | 2015-09-14 | Hepatitis C inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012087833A1 true WO2012087833A1 (en) | 2012-06-28 |
Family
ID=45476645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/065558 WO2012087833A1 (en) | 2010-12-22 | 2011-12-16 | Hepatitis c inhibitors and uses thereof |
Country Status (6)
Country | Link |
---|---|
US (3) | US9173887B2 (en) |
EP (1) | EP2655362A1 (en) |
JP (1) | JP5918264B2 (en) |
CN (2) | CN106986862A (en) |
CA (1) | CA2822357A1 (en) |
WO (1) | WO2012087833A1 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013119499A1 (en) * | 2012-02-08 | 2013-08-15 | Bristol-Myers Squibb Company | Novel compounds for the treatment of hepatitis c |
WO2014167009A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazole derivatives |
WO2014167008A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazolinthione derivatives |
WO2015038596A1 (en) | 2013-09-11 | 2015-03-19 | Emory University | Nucleotide and nucleoside compositions and uses related thereto |
WO2015086502A1 (en) * | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Pyrazolopyridine derivatives as modulators of tnf activity |
WO2016156290A1 (en) | 2015-04-02 | 2016-10-06 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
WO2016156294A1 (en) | 2015-04-02 | 2016-10-06 | Bayer Cropscience Aktiengesellschaft | Triazol derivatives as fungicides |
US9668481B2 (en) | 2013-04-12 | 2017-06-06 | Bayer Cropscience Aktiengesellschaft | Triazole derivatives |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2018050456A1 (en) | 2016-09-13 | 2018-03-22 | Bayer Cropscience Aktiengesellschaft | Active compound combinations comprising a 5-substituted imidazole derivative |
WO2018060073A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
WO2018060075A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection |
WO2018060074A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
WO2019092086A1 (en) | 2017-11-13 | 2019-05-16 | Bayer Aktiengesellschaft | Tetrazolylpropyl derivatives and their use as fungicides |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072853A1 (en) | 2000-12-15 | 2004-04-15 | Chamberlain Stanley D. | Therapeutic compounds |
WO2006010756A1 (en) | 2004-07-29 | 2006-02-02 | Ferrer Internacional, S. A. | Oxazolidinone compounds and compositions and methods related thereto |
US7265152B2 (en) | 2002-11-01 | 2007-09-04 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
WO2010030592A1 (en) * | 2008-09-11 | 2010-03-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
Family Cites Families (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3497597A (en) | 1967-08-01 | 1970-02-24 | American Cyanamid Co | Fungicidal composition and method containing 5-nitro-1,3,4-thiadiazoles |
DE3208437A1 (en) | 1982-03-09 | 1983-09-15 | Bayer Ag, 5090 Leverkusen | IMIDAZOTHIADIAZOLALKENCARBONIC ACID AMIDES, NEW INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS |
SE8704248D0 (en) | 1987-10-30 | 1987-10-30 | Haessle Ab | MEDICAL USE |
WO1991000092A1 (en) | 1989-06-13 | 1991-01-10 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
JP2778009B2 (en) | 1989-09-12 | 1998-07-23 | 株式会社リコー | Electrophotographic photoreceptor |
KR910011852A (en) | 1989-12-04 | 1991-08-07 | 폴 디. 매튜카이티스 | Imidazo [1,2-a] pyridinylalkyl compounds for the treatment of neurotoxin disorders |
US5716964A (en) | 1989-12-04 | 1998-02-10 | G.D. Searle & Co. | Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury |
WO1991019497A1 (en) | 1990-06-12 | 1991-12-26 | Smithkline Beecham Corporation | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
ES2095960T3 (en) | 1990-09-25 | 1997-03-01 | Rhone Poulenc Rorer Int | COMPOUNDS THAT HAVE ANTI-HYPERTENSIVE AND ANTI-ISCHEMICAL PROPERTIES. |
GB9026926D0 (en) | 1990-12-12 | 1991-01-30 | Smith Kline French Lab | Novel process |
AU9169991A (en) | 1990-12-13 | 1992-07-08 | Smithkline Beecham Corporation | Novel csaids |
AU9137591A (en) | 1990-12-13 | 1992-07-08 | Smithkline Beecham Corporation | Novel csaids |
US5240943A (en) | 1991-12-19 | 1993-08-31 | G. D. Searle & Co. | Benzopyran class iii antiarrhythmic agents |
WO1993025205A1 (en) | 1992-06-10 | 1993-12-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compounds for the treatment of anemia |
CA2116863A1 (en) | 1992-07-03 | 1994-01-20 | Sumio Yokota | Condensed heterocyclic derivatives and herbicides |
US5317028A (en) | 1992-09-08 | 1994-05-31 | Warner-Lambert Co. | 7-((substituted)amino)-8((substituted)carbonyl)-methylamino-1-oxaspiro(4,5)decanes useful in Parkinson's disease, dystonia, and other movement disorders |
TW253885B (en) | 1992-12-15 | 1995-08-11 | Ishihara Sangyo Kaisha | |
AU679045B2 (en) | 1993-03-18 | 1997-06-19 | Merck Sharp & Dohme Limited | Benzimidazole derivatives |
GB9316890D0 (en) | 1993-08-13 | 1993-09-29 | Pilkington Plc | Photochromic compounds |
GB9408577D0 (en) | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
WO1996019491A1 (en) | 1994-12-22 | 1996-06-27 | Biochem Pharma Inc. | Heterocyclic keto arginine peptides as thrombin inhibitors |
DK0823254T3 (en) | 1995-04-27 | 2002-11-04 | Fujisawa Pharmaceutical Co | Hitherto unknown use of pyrazolopyridine compounds |
JPH11505524A (en) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | Imidazo 1,2-A pyridine and imidazo 1,2-A pyrididine derivatives and their use as bone resorption inhibitors |
FR2735774B1 (en) | 1995-06-21 | 1997-09-12 | Sanofi Sa | USE OF HUMAN CB2 RECEPTOR AGONIST COMPOUNDS FOR THE PREPARATION OF IMMUNOMODULATORY DRUGS, NOVEL CB2 RECEPTOR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB9519077D0 (en) | 1995-09-18 | 1995-11-15 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
DE19547263C2 (en) | 1995-12-07 | 1999-04-29 | Cardiotec Inc | Amidinohydrazones of ketones derived from benzo [b] furan, processes for their preparation and medicaments containing these compounds |
EP0880519B1 (en) | 1996-01-22 | 2002-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them |
CA2244378A1 (en) | 1996-01-23 | 1997-07-31 | The Regents Of The University Of Michigan | Modified benzimidazole nucleosides as antiviral agents |
HUP9902645A3 (en) | 1996-03-18 | 1999-12-28 | Eisai Co Ltd | Fused-ring carboxylic acid derivatives |
AU2405697A (en) | 1996-04-25 | 1997-11-12 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for ischemic intestinal lesion and ileus |
GB9610813D0 (en) | 1996-05-23 | 1996-07-31 | Pharmacia Spa | Combinatorial solid phase synthesis of a library of benzufuran derivatives |
CN1227543A (en) | 1996-06-17 | 1999-09-01 | 美国家用产品公司 | Heterocyclylmethylamino derivatives of cyclobutene-3,4-diones as potassium channel modulators |
DE19624289A1 (en) | 1996-06-18 | 1998-01-02 | Merckle Gmbh | New fused pyrrolyl (e.g. pyrrolizine) acid, aldehyde or alcohol compounds |
WO1998001428A1 (en) | 1996-07-08 | 1998-01-15 | Du Pont Pharmaceuticals Company | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN |
ATE227277T1 (en) | 1996-08-21 | 2002-11-15 | Upjohn Co | ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTIMICROBES |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
US6303624B1 (en) | 1997-03-18 | 2001-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
ATE293609T1 (en) | 1997-05-30 | 2005-05-15 | Upjohn Co | ANTIBACTERIALLY EFFECTIVE OXAZOLIDINONE WITH A THIOCARBONYL FUNCTIONALITY |
US6255304B1 (en) | 1997-05-30 | 2001-07-03 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
WO1998055454A2 (en) | 1997-06-05 | 1998-12-10 | Takeda Chemical Industries, Ltd. | Benzofurans and benzothophenes as suppressors of neurodegeneration |
US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
GB9716244D0 (en) | 1997-07-31 | 1997-10-08 | Electrophoretics International | Pharmaceutical compounds |
US6080773A (en) | 1997-10-14 | 2000-06-27 | Akzo Nobel, N.V. | Benzylamine derivatives which are useful in treating psychiatric disorders |
US6630597B1 (en) | 1997-12-15 | 2003-10-07 | Transitions Optical, Inc. | Photochromic 6-aryl substituted 3H-naphtho(2,1-b)pyrans |
US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
WO1999059999A1 (en) | 1998-05-21 | 1999-11-25 | Shionogi & Co., Ltd. | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2 INHIBITORY EFFECT |
ATE342734T1 (en) | 1998-06-01 | 2006-11-15 | Astellas Pharma Inc | ADENOSINE A1 ANTAGONISTS AGAINST MALE STERILITY |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
US6410562B1 (en) | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
JP2001057292A (en) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | Luminescent element |
WO2001028666A1 (en) | 1999-10-19 | 2001-04-26 | Membrane Extraction Technology Limited | Process for removing and recovering of phenolic compounds from aqueous fluids |
JP2001139575A (en) | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | Novel pyrazolopyridine derivative |
US6461538B2 (en) | 1999-12-16 | 2002-10-08 | Fuji Photo Film Co., Ltd. | Production process for indolizine compounds and their use in organic light-emitting devices |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
DE60112272T2 (en) | 2000-04-27 | 2006-05-24 | Astellas Pharma Inc. | Imidazopyridine DERIVATIVES |
GB0017676D0 (en) * | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
DE10117183A1 (en) | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Use of substituted imidazo [1,2-a] pyridine compounds as medicaments |
CN100540538C (en) | 2001-04-16 | 2009-09-16 | 田边三菱制药株式会社 | The high conductance calcium-activated k channel is opened agent |
CA2452596C (en) | 2001-07-05 | 2010-12-21 | Takeda Chemical Industries, Ltd. | Benzo-fused 5-membered heterocyclic compounds, their production and use |
BR0212244A (en) | 2001-08-30 | 2004-10-05 | Merckle Gmbh | Use of one or more than one compound and its physiologically acceptable salts, derivatives and optical isomers, pharmaceutical composition, and method of treating or preventing degeneration or destruction of articular cartilage and / or subchondral bone in one or more joints of a mammal |
DK1447400T3 (en) | 2001-10-25 | 2008-12-08 | Asahi Kasei Pharma Corp | Bicyclic compound |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
TW200930291A (en) | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2004014908A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
US6828044B2 (en) | 2002-10-25 | 2004-12-07 | Eastman Kodak Company | Dopant in an electroluminescent device |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
BRPI0407216A (en) | 2003-02-27 | 2006-01-24 | Neurosearch As | Diazabically cyclic arila derivative, pharmaceutical composition, use of a diazabically cyclic arila derivative, and, method of treatment, prevention or alleviation of a disease or disorder or condition |
WO2005009389A2 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
ATE487475T1 (en) | 2003-08-01 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | HETEROCYCLIC COMPOUNDS AS USEFUL MALONYL-COA DECARBOXYLASE INHIBITORS |
WO2005014543A1 (en) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | Condensed ring compound and use thereof as hcv polymerase inhibitor |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
EP1663199B1 (en) | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
US7351726B2 (en) | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US7795242B2 (en) | 2003-10-15 | 2010-09-14 | The Brigham And Women's Hospital, Inc. | Methods and compositions for immunomodulation |
SE0303480D0 (en) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US7229480B2 (en) | 2004-02-13 | 2007-06-12 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
US20050256150A1 (en) | 2004-02-20 | 2005-11-17 | Vladimir Birman | Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
EP1746888A2 (en) | 2004-05-13 | 2007-01-31 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
MX2007007480A (en) | 2004-12-21 | 2007-07-20 | Hoffmann La Roche | Chroman derivatives and their use as 5-ht receptor ligands. |
US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
DE102005019181A1 (en) | 2005-04-25 | 2006-10-26 | Novartis Ag | New indene compound are peptide-deformylase inhibitors useful e.g. to treat or prevent diseases mediated by metalloproteinase activity and peptide-deformylase activity |
MY148644A (en) | 2005-07-18 | 2013-05-15 | Orion Corp | New pharmaceutical compounds |
US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7901793B2 (en) | 2005-09-23 | 2011-03-08 | Samsung Mobile Display Co., Ltd. | Organic light-emitting compound and organic light-emitting device containing the same |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PT1971601E (en) | 2005-11-15 | 2010-01-26 | Array Biopharma Inc | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
JP2009523729A (en) * | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | Treatment method for hepatitis C |
JP2009524689A (en) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | Compound |
US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
CA2644963A1 (en) | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
US7521443B2 (en) | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456167B2 (en) | 2006-05-25 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
RU2008152776A (en) | 2006-06-06 | 2010-07-20 | Эвиджен Инк. (Us) | Compounds of Substituted Pyrazole [1,5-a] Pyridine and Methods of Their Use |
US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008008907A2 (en) * | 2006-07-14 | 2008-01-17 | Genelabs Technologies, Inc. | Antiviral agents |
WO2008014219A2 (en) | 2006-07-24 | 2008-01-31 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as p13 kinase inhibitors |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | Novel imidazothiazoles and imidazoxazoles |
US20080107625A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US7994190B2 (en) | 2006-11-01 | 2011-08-09 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101195597A (en) | 2006-12-08 | 2008-06-11 | 中国科学院上海药物研究所 | 1-substituted-4,4-2 substituted thiosemicarbazide compounds, production method and uses of the same |
US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2008089125A2 (en) | 2007-01-15 | 2008-07-24 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases | Antiviral compounds and methods of using thereof |
US7541352B2 (en) | 2007-02-02 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7998951B2 (en) | 2007-03-05 | 2011-08-16 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7538102B2 (en) | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20100032886A (en) | 2007-06-08 | 2010-03-26 | 아보트 러보러터리즈 | 5-heteroaryl substituted indazoles as kinase inhibitors |
WO2008153129A1 (en) | 2007-06-14 | 2008-12-18 | Teijin Pharma Limited | Agent for lowering uric acid level |
US8143243B2 (en) | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7652004B2 (en) | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
HUE025976T2 (en) | 2007-09-27 | 2016-05-30 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazolothiadiazoles for use as protein kinase inhibitors |
US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8129367B2 (en) | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
US8093243B2 (en) | 2008-02-12 | 2012-01-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
BRPI0907885A2 (en) | 2008-02-14 | 2015-07-21 | Hoffmann La Roche | Hetrocyclic antiviral compounds |
KR100929642B1 (en) | 2008-02-20 | 2009-12-03 | 주식회사 하이닉스반도체 | Semiconductor device and manufacturing method thereof |
JP2009203203A (en) | 2008-02-29 | 2009-09-10 | Toyo Ink Mfg Co Ltd | Anthracene derivative and use thereof |
WO2009126691A1 (en) | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
JPWO2009128520A1 (en) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Heterocyclic compounds having PI3K inhibitory activity |
WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
US8133884B2 (en) | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR072008A1 (en) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | HETEROBICICLIC COMPOUNDS AS QUINASA P38 INHIBITION AGENTS |
WO2010002877A2 (en) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8453322B2 (en) | 2008-08-14 | 2013-06-04 | Ddi Global Corp. | Manufacturing methods of multilayer printed circuit board having stacked via |
US20100056491A1 (en) | 2008-08-29 | 2010-03-04 | Memory Pharmaceuticals Corporation | 4'-amino cyclic compounds having 5-ht6 receptor affinity |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7994171B2 (en) | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP5416944B2 (en) | 2008-10-23 | 2014-02-12 | ユー・ディー・シー アイルランド リミテッド | Organic electroluminescence device |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
TWI438200B (en) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Hepatitis c virus inhibitors |
TWI476190B (en) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Hepatitis c virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
-
2011
- 2011-12-16 CN CN201610903761.7A patent/CN106986862A/en active Pending
- 2011-12-16 US US13/995,701 patent/US9173887B2/en active Active
- 2011-12-16 CN CN201180068128.6A patent/CN103649079B/en not_active Expired - Fee Related
- 2011-12-16 WO PCT/US2011/065558 patent/WO2012087833A1/en active Application Filing
- 2011-12-16 JP JP2013546262A patent/JP5918264B2/en not_active Expired - Fee Related
- 2011-12-16 EP EP11808073.8A patent/EP2655362A1/en not_active Withdrawn
- 2011-12-16 CA CA2822357A patent/CA2822357A1/en not_active Abandoned
-
2015
- 2015-09-14 US US14/852,984 patent/US9453007B2/en active Active
-
2016
- 2016-08-18 US US15/240,753 patent/US9567355B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072853A1 (en) | 2000-12-15 | 2004-04-15 | Chamberlain Stanley D. | Therapeutic compounds |
US7265152B2 (en) | 2002-11-01 | 2007-09-04 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
WO2006010756A1 (en) | 2004-07-29 | 2006-02-02 | Ferrer Internacional, S. A. | Oxazolidinone compounds and compositions and methods related thereto |
WO2010030592A1 (en) * | 2008-09-11 | 2010-03-18 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
Non-Patent Citations (20)
Title |
---|
"Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2005, LIPPINCOTT WILLIAMS & WILKINS |
CAPRETTA A ET AL., J. ORG. CHEM., vol. 69, 2004, pages 5082 |
FIORINO, F ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, pages 2978 - 2982 |
FUJIOKA H ET AL., TETRAHEDRON LETTERS, vol. 46, 2005, pages 2197 - 2200 |
GREENE TW; WUTS PGM: "Protective Groups in Organic Synthesis(3rd ed.,", 1999, JOHN WILEY & SONS |
GUDMUNDSSON KS ET AL., BIOORG. MED. CHEM. LETT., vol. 18, 2008, pages 1157 - 1161 |
HOOVER, J.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO. |
ISHIHARA M ET AL., SYNLETT, 2006, pages 227 - 230 |
KAMITORI Y ET AL., J ORGANIC CHEMISTRY, vol. 53, 1988, pages 129 - 135 |
KHABNADIDEH S ET AL., BIOORG. MED. CHEM., vol. 13, 2005, pages 2637 - 2649 |
KNAPP S ET AL., J. ORG. CHEM., vol. 58, 1993, pages 997 - 998 |
LOHMAN V ET AL., SCIENCE, vol. 285, no. 5424, 1999, pages 110 - 113 |
MIDDLETON T ET AL., J. VIROLOGICAL METHODS, vol. 145, no. 2, 2007, pages 137 - 145 |
ORG. LETT., vol. 5, 2003, pages 953 |
PARRICK J ET AL., J. CHEM. RESEARCH (SYNOPSES, 1990, pages 64 - 65 |
QUAN ML ET AL., J. MED. CHEM., vol. 48, 2005, pages 1729 - 1744 |
ROMINE JL ET AL., J. MED. CHEM., vol. 50, 2007, pages 528 - 542 |
SLIWA ET AL., JOURNAL OF CHEMICAL RESEARCH, 1982, pages 2515 - 2527 |
TAKACS, K. ET AL., CHEMISCHE BERICHTE, vol. 108, 1975, pages 1911 - 1923 |
YUE, D, J. ORG. CHEM., vol. 70, 2005, pages 10292 - 10296 |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2013119499A1 (en) * | 2012-02-08 | 2013-08-15 | Bristol-Myers Squibb Company | Novel compounds for the treatment of hepatitis c |
US9550752B2 (en) | 2013-04-12 | 2017-01-24 | Bayer Cropscience Aktiengesellschaft | Triazolinthione derivatives |
WO2014167009A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazole derivatives |
WO2014167008A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazolinthione derivatives |
US9822099B2 (en) | 2013-04-12 | 2017-11-21 | Bayer Cropscience Aktiengesellschaft | Triazole derivatives |
US9668481B2 (en) | 2013-04-12 | 2017-06-06 | Bayer Cropscience Aktiengesellschaft | Triazole derivatives |
WO2015038596A1 (en) | 2013-09-11 | 2015-03-19 | Emory University | Nucleotide and nucleoside compositions and uses related thereto |
EP4094767A1 (en) | 2013-09-11 | 2022-11-30 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
RU2684641C1 (en) * | 2013-12-09 | 2019-04-11 | Юсб Байофарма Спрл | Pyrazolopyridine derivatives as modulators of tnf activity |
US9902720B2 (en) | 2013-12-09 | 2018-02-27 | Ucb Biopharma Sprl | Pyrazolopyridine derivatives as modulators of TNF activity |
JP2016539977A (en) * | 2013-12-09 | 2016-12-22 | ユーシービー バイオファルマ エスピーアールエル | Pyrazolopyridine derivatives as modulators of TNF activity |
WO2015086502A1 (en) * | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Pyrazolopyridine derivatives as modulators of tnf activity |
WO2016156290A1 (en) | 2015-04-02 | 2016-10-06 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
WO2016156294A1 (en) | 2015-04-02 | 2016-10-06 | Bayer Cropscience Aktiengesellschaft | Triazol derivatives as fungicides |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2018050456A1 (en) | 2016-09-13 | 2018-03-22 | Bayer Cropscience Aktiengesellschaft | Active compound combinations comprising a 5-substituted imidazole derivative |
WO2018060074A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
WO2018060075A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection |
WO2018060073A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
US11833156B2 (en) | 2017-09-22 | 2023-12-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
US11426412B2 (en) | 2017-10-18 | 2022-08-30 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
WO2019092086A1 (en) | 2017-11-13 | 2019-05-16 | Bayer Aktiengesellschaft | Tetrazolylpropyl derivatives and their use as fungicides |
US11459338B2 (en) | 2017-11-24 | 2022-10-04 | Jubilant Episcribe Llc | Heterocyclic compounds as PRMT5 inhibitors |
US11529341B2 (en) | 2018-03-13 | 2022-12-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
Also Published As
Publication number | Publication date |
---|---|
EP2655362A1 (en) | 2013-10-30 |
US9567355B2 (en) | 2017-02-14 |
US20160355530A1 (en) | 2016-12-08 |
CN103649079A (en) | 2014-03-19 |
US20160002213A1 (en) | 2016-01-07 |
US9453007B2 (en) | 2016-09-27 |
US20140038919A1 (en) | 2014-02-06 |
JP2014500322A (en) | 2014-01-09 |
CN106986862A (en) | 2017-07-28 |
JP5918264B2 (en) | 2016-05-18 |
CA2822357A1 (en) | 2012-06-28 |
CN103649079B (en) | 2016-11-16 |
US9173887B2 (en) | 2015-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9567355B2 (en) | Hepatitis C inhibitors and uses thereof | |
EP2753618B1 (en) | Heterocyclic-substitued benzofuran derivatives and methods of use thereof for the treatment of viral diseases | |
EP2753611B1 (en) | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases | |
EP2753325B1 (en) | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases | |
US9555038B2 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | |
AU2007213451A1 (en) | Treatment of duchenne muscular dystrophy | |
WO2011066241A1 (en) | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases | |
WO2017177004A1 (en) | Tertiary amides and method of use | |
WO2018035005A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | |
EP3393585A1 (en) | Silane-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11808073 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2822357 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013546262 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/007359 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011808073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011808073 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13995701 Country of ref document: US |